

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 21/04; C12N 9/18, 15/31, 15/55		A1	(11) International Publication Number: WO 98/42728
			(43) International Publication Date: 1 October 1998 (01.10.98)
(21) International Application Number: PCT/US98/05814		(74) Agents: OLDENKAMP, David, J. et al.; Oppenheimer Wolff & Donnelly LLP, Suite 3800, 2029 Century Park East, Los Angeles, CA 90067 (US).	
(22) International Filing Date: 25 March 1998 (25.03.98)			
(30) Priority Data: 60/041,666 25 March 1997 (25.03.97) US 60/045,211 30 April 1997 (30.04.97) US 60/046,256 12 May 1997 (12.05.97) US 08/905,359 4 August 1997 (04.08.97) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SO, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): CALIFORNIA INSTITUTE OF TECHNOLOGY [US/US]; 1201 E. California Boulevard, Pasadena, CA 91125 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): ARNOLD, Frances, H. [US/US]; 629 S. Grand Avenue, Pasadena, CA 91106 (US). SHAO, Zhixin [CN/CN]; 110 S. Michigan Avenue, #7, Pasadena, CA 91106 (US). AFFHOLTER, Joseph, A. [US/US]; 823 E. Sanford Road, Midland, MI 48642 (US). ZHAO, Huimin [CN/CN]; 1324 Cordova Street, Pasadena, CA 91106 (US). GIVER, Lorraine, J. [US/US]; 140 S. Catalina Avenue #4, Pasadena, CA 91106 (US).			
(54) Title: RECOMBINATION OF POLYNUCLEOTIDE SEQUENCES USING RANDOM OR DEFINED PRIMERS			
(57) Abstract <p>A method for <i>in vitro</i> mutagenesis and recombination of polynucleotide sequences based on polymerase-catalyzed extension of primer oligonucleotides is disclosed. The method involves priming template polynucleotide(s) with random-sequences or defined-sequence primers to generate a pool of short DNA fragments with a low level of point mutations. The DNA fragments are subjected to denaturation followed by annealing and further enzyme-catalyzed DNA polymerization. This procedure is repeated a sufficient number of times to produce full-length genes which comprise mutants of the original template polynucleotides. These genes can be further amplified by the polymerase chain reaction and cloned into a vector for expression of the encoded proteins.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

RECOMBINATION OF POLYNUCLEOTIDE SEQUENCES USING RANDOM OR DEFINED PRIMERS

The U.S. Government has certain rights in this invention pursuant to Grant No. DE-FG02-93-CH10578 awarded by the Department of Energy and Grant No. N00014-96-1-0340 awarded by the Office of Naval Research.

5

BACKGROUND OF THE INVENTION

This application is a continuation-in-part of pending U.S. patent applications, Serial numbers 60/041,666, filed March 25, 1997; 60/045,211, filed April 30, 1997; 60/046,256, filed May 12, 1997; and 08/905, 359, filed August 4, 1997.

10

1. Field of the Invention

The present invention relates generally to *in vitro* methods for mutagenesis and recombination of polynucleotide sequences. More particularly, the present invention involves a simple and efficient method for *in vitro* mutagenesis and recombination of polynucleotide sequences based on polymerase-catalyzed extension of primer oligonucleotides, followed by gene assembly and optional gene amplification.

15

2. Description of Related Art

20

The publications and other reference materials referred to herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference. For convenience, the reference materials are numerically referenced and grouped in the appended bibliography.

25

30

Proteins are engineered with the goal of improving their performance for practical applications. Desirable properties depend on the application of interest and may include tighter binding to a receptor, high catalytic activity, high stability, the ability to accept a wider (or narrower) range of substrates, or the ability to function in nonnatural environments such as organic solvents. A variety of approaches, including 'rational' design and random mutagenesis methods, have been successfully used to optimize protein functions (1). The choice of approach for a given optimization problem will depend upon the degree of understanding of the relationships between sequence, structure and function. The rational redesign of an enzyme catalytic site, for example, often

requires extensive knowledge of the enzyme structure, the structures of its complexes with various ligands and analogs of reaction intermediates and details of the catalytic mechanism. Such information is available only for a very few well-studied systems; little is known about the vast majority of potentially interesting enzymes. Identifying the amino acids responsible for existing protein functions and those which might give rise to new functions remains an often-overwhelming challenge. This, together with the growing appreciation that many protein functions are not confined to a small number of amino acids, but are affected by residues far from active sites, has prompted a growing number of groups to turn to random mutagenesis, or 'directed' evolution, to engineer novel proteins (1).

Various optimization procedures such as genetic algorithms (2,3) and evolutionary strategies (4,5) have been inspired by natural evolution. These procedures employ mutation, which makes small random changes in members of the population, as well as crossover, which combines properties of different individuals, to achieve a specific optimization goal. There also exist strong interplays between mutation and crossover, as shown by computer simulations of different optimization problems (6-9). Developing efficient and practical experimental techniques to mimic these key processes is a scientific challenge. The application of such techniques should allow one, for example, to explore and optimize the functions of biological molecules such as proteins and nucleic acids, *in vivo* or even completely free from the constraints of a living system (10,11).

Directed evolution, inspired by natural evolution, involves the generation and selection or screening of a pool of mutated molecules which has sufficient diversity for a molecule encoding a protein with altered or enhanced function to be present therein. It generally begins with creation of a library of mutated genes. Gene products which show improvement with respect to the desired property or set of properties are identified by selection or screening. The gene(s) encoding those products can be subjected to further cycles of the process in order to accumulate beneficial mutations. This evolution can involve few or many generations, depending on how far one wishes to progress and the effects of mutations typically observed in each generation. Such approaches have been used to create novel functional nucleic acids (12), peptides and other small molecules (12), antibodies (12), as well as enzymes and other proteins (13,14,16). Directed evolution requires little specific knowledge about the product itself, only a means to evaluate the

function to be optimized. These procedures are even fairly tolerant to inaccuracies and noise in the function evaluation (15).

5 The diversity of genes for directed evolution can be created by introducing new point mutations using a variety of methods, including mutagenic PCR (15) or combinatorial cassette mutagenesis (16). The ability to recombine genes, however, can add an important dimension to the evolutionary process, as evidenced by its key role in natural evolution. Homologous recombination is an important natural process in which organisms exchange genetic information between related genes, increasing the
10 accessible genetic diversity within a species. While introducing potentially powerful adaptive and diversification competencies into their hosts, such pathways also operate at very low efficiencies, often eliciting insignificant changes in pathway structure or function, even after tens of generations. Thus, while such mechanisms prove beneficial to host organisms/species over geological time spans, *in vivo* recombination methods represent cumbersome,
15 if not unusable, combinatorial processes for tailoring the performance of enzymes or other proteins not strongly linked to the organism's intermediary metabolism and survival.

Several groups have recognized the utility of gene recombination in directed evolution. Methods for *in vivo* recombination of genes are disclosed,
20 for example, in published PCT application WO 97/07205 and US Pat. No. 5,093,257. As discussed above, these *in vivo* methods are cumbersome and poorly optimized for rapid evolution of function. Stemmer has disclosed a method for *in vitro* recombination of related DNA sequences in which the parental sequences are cut into fragments, generally using an enzyme such as
25 DNase I, and are reassembled (17,18,19). The non-random DNA fragmentation associated with DNase I and other endonucleases, however, introduces bias into the recombination and limits the recombination diversity.

Furthermore, this method is limited to recombination of double-stranded polynucleotides and cannot be used on single-stranded templates. Further,
30 this method does not work well with certain combinations of genes and primers. It is not efficient for recombination of short sequences (less than 200 nucleotides (nts)), for example. Finally, it is quite laborious, requiring several steps. Alternative, convenient methods for creating novel genes by point
35 mutagenesis and recombination *in vitro* are needed.

SUMMARY OF THE INVENTION

The present invention provides a new and significantly improved approach to creating novel polynucleotide sequences by point mutation and recombination *in vitro* of a set of parental sequences (the templates). The novel polynucleotide sequences can be useful in themselves (for example, for DNA-based computing), or they can be expressed in recombinant organisms for directed evolution of the gene products. One embodiment of the invention involves priming the template gene(s) with random-sequence oligonucleotides to generate a pool of short DNA fragments. Under appropriate reaction conditions, these short DNA fragments can prime one another based on complementarity and thus can be reassembled to form full-length genes by repeated thermocycling in the presence of thermostable DNA polymerase. These reassembled genes, which contain point mutations as well as novel combinations of sequences from different parental genes, can be further amplified by conventional PCR and cloned into a proper vector for expression of the encoded proteins. Screening or selection of the gene products leads to new variants with improved or even novel functions. These variants can be used as they are, or they can serve as new starting points for further cycles of mutagenesis and recombination.

A second embodiment of the invention involves priming the template gene(s) with a set of primer oligonucleotides of defined sequence or defined sequence exhibiting limited randomness to generate a pool of short DNA fragments, which are then reassembled as described above into full length genes.

A third embodiment of the invention involves a novel process we term the 'staggered extension' process, or StEP. Instead of reassembling the pool of fragments created by the extended primers, full-length genes are assembled directly in the presence of the template(s). The StEP consists of repeated cycles of denaturation followed by extremely abbreviated annealing/extension steps. In each cycle the extended fragments can anneal to different templates based on complementarity and extend a little further to create "recombinant cassettes." Due to this template switching, most of the polynucleotides contain sequences from different parental genes (i.e. are novel recombinants). This process is repeated until full-length genes form. It can be followed by an optional gene amplification step.

The different embodiments of the invention provide features and advantages for different applications. In the most preferred embodiment, one or more defined primers or defined primers exhibiting limited randomness

which correspond to or flank the 5' and 3' ends of the template polynucleotides are used with StEP to generate gene fragments which grow into the novel full-length sequences. This simple method requires no knowledge of the template sequence(s).

5 In another preferred embodiment, multiple defined primers or defined primers exhibiting limited randomness are used to generate short gene fragments which are reassembled into full-length genes. Using multiple defined primers allows the user to bias *in vitro* recombination frequency. If sequence information is available, primers can be designed to generate
10 overlapping recombination cassettes which increase the frequency of recombination at particular locations. Among other features, this method introduces the flexibility to take advantage of available structural and functional information as well as information accumulated through previous generations of mutagenesis and selection (or screening).

15 In addition to recombination, the different embodiments of the primer-based recombination process will generate point mutations. It is desirable to know and be able to control this point mutation rate, which can be done by manipulating the conditions of DNA synthesis and gene reassembly. Using the defined-primer approach, specific point mutations can also be directed to
20 specific positions in the sequence through the use of mutagenic primers.

The various primer-based recombination methods in accordance with this invention have been shown to enhance the activity of *Actinoplanes utahensis* ECB deacylase over a broad range of pH values and in the presence of organic solvent and to improve the thermostability of *Bacillus subtilis*
25 subtilisin E. DNA sequencing confirms the role of point mutation and recombination in the generation of novel sequences. These protocols have been found to be both simple and reliable.

The above discussed and many other features and attendant advantages will become better understood by reference to the following
30 detailed description when taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts recombination in accordance with the present invention
35 using random-sequence primers and gene reassembly. The steps shown are:
a) Synthesis of single-stranded DNA fragments using mesophilic or thermophilic polymerase with random-sequence oligonucleotides as primers (primers not shown); b) Removal of templates; c) Reassembly with

thermophilic DNA polymerase; d) Amplification with thermostable polymerase(s); e) Cloning and Screening (optional); and f) Repeat the process with selected gene(s) (optional).

5 FIG. 2 depicts recombination in accordance with the present invention using defined primers. The method is illustrated for the recombination of two genes, where x = mutation. The steps diagrammed are: a) The genes are primed with defined primers in PCR reactions that can be done separately (2 primers per reaction) or combined (multiple primers per reaction); c) Initial products are formed until defined primers are exhausted. Template is removed (optional); d) Initial fragments prime and extend themselves in further cycles of PCR with no addition of external primers. Assembly continues until full-length genes are formed; e) (optional) Full-length genes are amplified in a PCR reaction with external primers; f) (optional) Repeat the process with selected gene(s).

20 FIG. 3 depicts recombination in accordance with the present invention using two defined flanking primers and StEP. Only one primer and two single strands from two templates are shown here to illustrate the recombination process. The outlined steps are: a) After denaturation, template genes are primed with one defined primer; b) Short fragments are produced by primer extension for a short time; c) In the next cycle of StEP, fragments are randomly primed to the templates and extended further; d) Denaturation and annealing/extension is repeated until full-length genes are made (visible on an agarose gel); e) Full-length genes are purified, or amplified in a PCR reaction with external primers (optional); f) (optional) Repeat the process with selected gene(s).

30 FIG. 4 is a diagrammatic representation of the results of the recombination of two genes using two flanking primers and staggered extension in accordance with the present invention. DNA sequences of five genes chosen from the recombined library are indicated, where x is a mutation present in the parental genes, and the triangle represents a new point mutation.

35 FIG. 5 is a diagrammatic representation of the sequences of the pNB esterase genes described in Example 3. Template genes 2-13 and 5-B12 were recombined using the defined primer approach. The positions of the primers

are indicated by arrows, and the positions where the parental sequences differ from one another are indicated by x's. New point mutations are indicated by triangles. Mutations identified in these recombined genes are listed (only positions which differ in the parental sequences are listed). Both 6E6 and 6H1 are recombination products of the template genes.

FIG. 6 shows the positions and sequences of the four defined internal primers used to generate recombined genes from template genes R1 and R2 by interspersed primer-based recombination. Primer P50F contains a mutation (A→T at base position 598) which simultaneously eliminates a HindIII restriction site and adds a new unique NheI site. Gene R2 also contains a mutation A→G at the same base position, which eliminates the HindIII site.

FIG. 7 is an electrophoresis gel which shows the results of the restriction-digestion analysis of plasmids from the 40 clones.

FIG. 8 shows the results of sequencing ten genes from the defined primer-based recombination library. Lines represent 986-bp of subtilisin E gene including 45 nt of its prosequence, the entire mature sequence and 113 nt after the stop codon. Crosses indicate positions of mutations from parent gene R1 and R2, while triangles indicate positions of new point mutations introduced during the recombination procedure. Circles represent the mutation introduced by the mutagenic primer P50F.

FIG. 9 depicts the results of applying the random-sequence primer recombination method to the gene for *Actinoplanes utahensis* ECB deacylase. (a) The 2.4 kb ECB deacylase gene was purified from an agarose gel. (b) The size of the random priming products ranged from 100 to 500 bases. (c) Fragments shorter than 300 bases were isolated. (d) The purified fragments were used to reassemble the full-length gene with a smear background. (e) A single PCR product of the same size as the ECB deacylase gene was obtained after conventional PCR with the two primers located at the start and stop regions of this gene. (f) After digestion with *Xho*I and *Psh*AI, the PCR product was cloned into a modified pJ702 vector to form a mutant library. (g) Introducing this library into *Streptomyces lividans* TK23 resulted in approximately 71% clones producing the active ECB deacylase.

FIG. 10 shows the specific activity of the wild-type ECB deacylase and mutant M16 obtained in accordance with the present invention.

5 FIG. 11 shows pH profiles of activity of the wild-type ECB deacylase and mutant M16 obtained in accordance with the present invention.

10 FIG.12 shows the DNA sequence analysis of 10 clones randomly chosen from the library/Klenow. Lines represent 986-bp of subtilisin E gene including 45 nt of its prosequence, the entire mature sequence and 113 nt after the stop codon. Crosses indicate positions of mutations from R1 and R2, while triangles indicate positions of new point mutations introduced during the random-priming recombination process.

15 FIG.13 Thermostability index profiles of the screened clones from the five libraries produced using different polymerases: a) library/Klenow, b) library/T4, c) library/Sequenase, d) library/Stoffel and e) library/Pfu. Normalized residual activity (A_r/A_i) after incubation at 65°C was used as an index of the enzyme thermostability. Data were sorted and plotted in descending order.

20

DETAILED DESCRIPTION OF THE INVENTION

In one preferred embodiment of the present invention, a set of primers with all possible nucleotide sequence combinations ($(dp(N))_L$ where L = primer length) is used for the primer-based recombination. It has been known for years that oligodeoxynucleotides of different lengths can serve as primers for initiation of DNA synthesis on single-stranded templates by the Klenow fragment of *E.coli* polymerase I (21). Although they are smaller than the size of a normal PCR primer (i.e. less than 13 bases), oligomers as short as hexanucleotides can adequately prime the reaction and are frequently used in labeling reactions (22). The use of random primers to create a pool of gene fragments followed by gene reassembly in accordance with the invention is shown in FIG. 1. The steps include generation of diverse "breeding blocks" from the single-stranded polynucleotide templates through random priming, reassembly of the full-length DNA from the generated short, nascent DNA fragments by thermocycling in the presence of DNA polymerase and nucleotides, and amplification of the desired genes from the reassembled

25

30

35

products by conventional PCR for further cloning and screening. This procedure introduces new mutations mainly at the priming step but also during other steps. These new mutations and the mutations already present in the template sequences are recombined during reassembly to create a library of novel DNA sequences. The process can be repeated on the selected sequences, if desired.

To carry out the random priming procedure, the template(s) can be single- or denatured double-stranded polynucleotide(s) in linear or closed circular form. The templates can be mixed in equimolar amounts, or in amounts weighted, for example, by their functional attributes. Since, at least in some cases, the template genes are cloned in vectors into which no additional mutations should be introduced, they are usually first cleaved with restriction endonuclease(s) and purified from the vectors. The resulting linear DNA molecules are denatured by boiling, annealed to random-sequence oligodeoxynucleotides and incubated with DNA polymerase in the presence of an appropriate amount of dNTPs. Hexanucleotide primers are preferred, although longer random primers (up to 24 bases) may also be used, depending on the DNA polymerase and conditioning used during random priming synthesis. Thus the oligonucleotides prime the DNA of interest at various positions along the entire target region and are extended to generate short DNA fragments complementary to each strand of the template DNA. Due to events such as base mis-incorporations and mispriming, these short DNA fragments also contain point mutations. Under routinely established reaction conditions, the short DNA fragments can prime one another based on homology and be reassembled into full-length genes by repeated thermocycling in the presence of thermostable DNA polymerase. The resulting full-length genes will have diverse sequences, most of which, however, still resemble that of the original template DNA. These sequences can be further amplified by a conventional PCR and cloned into a vector for expression. Screening or selection of the expressed mutants should lead to variants with improved or even new specific functions. These variants can be immediately used as partial solutions to a practical problem, or they can serve as new starting points for further cycles of directed evolution.

Compared to other techniques used for protein optimization, such as combinatorial cassette and oligonucleotide-directed mutagenesis (24,25,26), error-prone PCR (27, 28), or DNA shuffling (17,18,19), some of the advantages of the random-primer based procedure for *in vitro* protein evolution are summarized as follows:

1. The template(s) used for random priming synthesis may be either single- or double-stranded polynucleotides. In contrast, error-prone PCR and the DNA shuffling method for recombination (17,18,19) necessarily employ only double-stranded polynucleotides. Using the technique described
5 here, mutations and/or crossovers can be introduced at the DNA level by using different DNA-dependent DNA polymerases, or even directly from mRNA by using different RNA-dependent DNA polymerases. Recombination can be performed using single-stranded DNA templates.

2. In contrast to the DNA shuffling procedure, which requires
10 fragmentation of the double-stranded DNA template (generally done with DNase I) to generate random fragments, the technique described here employs random priming synthesis to obtain DNA fragments of controllable size as "breeding blocks" for further reassembly (FIG. 1). One immediate advantage is that two sources of nuclease activity (DNase I and 5'-3' exonuclease) are
15 eliminated, and this allows easier control over the size of the final reassembly and amplification gene fragments.

3. Since the random primers are a population of synthetic oligo-nucleotides that contain all four bases in every position, they are uniform in their length and lack a sequence bias. The sequence heterogeneity allows
20 them to form hybrids with the template DNA strands at many positions, so that every nucleotide of the template (except, perhaps, those at the extreme 5' terminus) should be copied at a similar frequency into products. In this way, both mutations and crossover may happen more randomly than, for example, with error-prone PCR or DNA shuffling.

4. The random-primed DNA synthesis is based on the hybridization
25 of a mixture of hexanucleotides to the DNA templates, and the complementary strands are synthesized from the 3'-OH termini at the random hexanucleotide primer using polymerase and the four deoxynucleotide triphosphates. Thus the reaction is independent of the length of the DNA template. DNA fragments
30 of 200 bases length can be primed equally well as linearized plasmid or λ DNA (29). This is particularly useful for engineering peptides, for example.

5. Since DNase I is an endonuclease that hydrolyzes double-stranded DNA preferentially at sites adjacent to pyrimidine nucleotides, its use
35 in DNA shuffling may result in bias (particularly for genes with high G+C or high A+T content) at the step of template gene digestion. Effects of this potential bias on the overall mutation rate and recombination frequency may be avoided by using the random-priming approach. Bias in random priming

due to preferential hybridization to GC-rich regions of the template DNA could be overcome by increasing the A and T content in the random oligonucleotide library.

5 An important part of practicing the present invention is controlling the average size of the nascent, single-strand DNA synthesized during the random priming process. This step has been studied in detail by others. Hodgson and Fisk (30) found that the average size of the synthesized single-strand DNA is an inverse function of primer concentration: $\text{length} = k / \sqrt{\ln P_c}$, where P_c is the primer concentration. The inverse relationship between primer concentration and output DNA fragment size may be due to steric hindrance. Based on this guideline, proper conditions for random-priming synthesis can be readily set for individual genes of different lengths.

10 Since dozens of polymerases are currently available, synthesis of the short, nascent DNA fragments can be achieved in a variety of fashions. For example, bacteriophage T4 DNA polymerase (23) or T7 sequenase version 2.0 DNA polymerase (31,32) can be used for the random priming synthesis.

For single-stranded polynucleotide templates (particularly for RNA templates), a reverse transcriptase is preferred for random-priming synthesis. Since this enzyme lacks 3'→5' exonuclease activity, it is rather prone to error.

20 In the presence of high concentrations of dNTPs and Mn^{2+} , about 1 base in every 500 is misincorporated (29).

By modifying the reaction conditions, the PCR can be adjusted for the random priming synthesis using thermostable polymerase for the short, nascent DNA fragments. An important consideration is to identify by routine experimentation the reaction conditions which ensure that the short random primers can anneal to the templates and give sufficient DNA amplification at higher temperatures. We have found that random primers as short as $dp(N)_{12}$ can be used with PCR to generate the extended primers. Adapting the PCR to the random priming synthesis provides a convenient method to make short, nascent DNA fragments and makes this random priming recombination technique very robust.

25 30

In many evolution scenarios, recombination should be conducted between oligonucleotide sequences for which sequence information is available for at least some of the template sequences. In such scenarios, it is often possible to define and synthesize a series of primers which are interspersed between the various mutations. When defined primers are used, they can be

35

between 6 and 100 bases long. In accordance with the present invention, it was discovered that by allowing these defined primers to initiate a series of overlapping primer extension reactions (which may be facilitated by thermocycling), it is possible to generate recombination cassettes each containing one or more of the accumulated mutations, allelic or isotypic differences between templates. Using the defined primers in such a way that overlapping extension products are generated in the DNA polymerization reactions, exhaustion of available primer leads to the progressive cross-hybridization of primer extended products until complete gene products are generated. The repeated rounds of annealing, extension and denaturation assure recombination of each overlapping cassette with every other.

A preferred embodiment of the present invention involves methods in which a set of defined oligonucleotide primers is used to prime DNA synthesis. FIG. 2 illustrates an exemplary version of the present invention in which defined primers are used. Careful design and positioning of oligonucleotide primers facilitates the generation of non-random extended recombination primers and is used to determine the major recombination (co-segregation) events along the length of homologous templates.

Another embodiment of the present invention is an alternative approach to primer-based gene assembly and recombination in the presence of template. Thus, as illustrated in FIG. 3, the present invention includes recombination in which enzyme-catalyzed DNA polymerization is allowed to proceed only briefly (by limiting the time and lowering the temperature of the extension step) prior to denaturation. Denaturation is followed by random annealing of the extended fragments to template sequences and continued partial extension. This process is repeated multiple times, depending on the concentration of primer and template, until full length sequences are made. This process is called staggered extension, or StEP. Although random primers can also be used for StEP, gene synthesis is not nearly as efficient as with defined primers. Thus defined primers are preferred.

In this method, a brief annealing/extension step(s) is used to generate the partially extended primer. A typical annealing/extension step is done under conditions which allow high fidelity primer annealing ($T_{\text{annealing}}$ greater than T_m ⁻²⁵), but limit the polymerization/extension to no more than a few seconds (or an average extension to less than 300 nts). Minimum extensions are preferably on the order of 20-50 nts. It has been demonstrated that thermostable DNA polymerases typically exhibit maximal polymerization rates

of 100-150 nucleotides/second/enzyme molecule at optimal temperatures, but follow approximate Arrhenius kinetics at temperatures approaching the optimum temperature (T_{opt}). Thus, at a temperature of 55°C, a thermostable polymerase exhibits only 20-25% of the steady state polymerization rate that it exhibits at 72°C (T_{opt}), or 24 nts/second (40). At 37°C and 22°C, *Taq* polymerase is reported to have extension activities of 1.5 and 0.25 nts/second, respectively (24). Both time and temperature can be routinely altered based on the desired recombination events and knowledge of basic polymerase kinetics and biochemistry.

The progress of the staggered extension process is monitored by removing aliquots from the reaction tube at various time points in the primer extension and separating DNA fragments by agarose gel electrophoresis. Evidence of effective primer extension is seen from the appearance of a low molecular weight 'smear' early in the process which increases in molecular weight with increasing cycle number.

Unlike the gene amplification process (which generates new DNA exponentially), StEP generates new DNA fragments in an additive manner in its early cycles which contain DNA segments corresponding to the different template genes. Under non-amplifying conditions, 20 cycles of StEP generates a maximal molar yield of DNA of approximately 40 times the initial template concentration. In comparison, the idealized polymerase chain reaction process for gene amplification is multiplicative throughout, giving a maximal molar yield of approximately 1×10^6 -fold through the same number of steps. In practice, the difference between the two processes can be observed by PCR, giving a clear 'band' after only a few (less than 10) cycles when starting with template at concentrations of less than 1 ng/ul and primers at 10-500-fold excess (vs. 10^6 -fold excess typical of gene amplification). Under similar reaction conditions, the StEP would be expected to give a less visible 'smear', which increases in molecular weight with increasing number of cycles. When significant numbers of primer extended DNA molecules begin to reach sizes of greater than 1/2 the length of the full length gene, a rapid jump in molecular weight occurs, as half-extended forward and reverse strands begin to cross-hybridize to generate fragments nearly 2 times the size of those encountered to that point in the process. At this point, consolidation of the smear into a discrete band of the appropriate molecular weight can occur rapidly by either

continuing to subject the DNA to StEP, or altering the thermocycle to allow complete extension of the primed DNA to drive exponential gene amplification.

Following gene assembly (and, if necessary, conversion to double stranded form) recombined genes are amplified (optional), digested with
5 suitable restriction enzymes and ligated into expression vectors for screening of the expressed gene products. The process can be repeated if desired, in order to accumulate sequence changes leading to the evolution of desired functions.

The staggered extension and homologous gene assembly process (StEP)
10 represents a powerful, flexible method for recombining similar genes in a random or biased fashion. The process can be used to concentrate recombination within or away from specific regions of a known series of sequences by controlling placement of primers and the time allowed for annealing/extension steps. It can also be used to recombine specific cassettes
15 of homologous genetic information generated separately or within a single reaction. The method is also applicable to recombining genes for which no sequence information is available but for which functional 5' and 3' amplification primers can be prepared. Unlike other recombination methods, the staggered extension process can be run in a single tube using
20 conventional procedures without complex separation or purification steps.

Some of the advantages of the defined-primer embodiments of the present invention are summarized as follows:

1. The StEP method does not require separation of parent
molecules from assembled products.
- 25 2. Defined primers can be used to bias the location of recombination events.
3. StEP allows the recombination frequency to be adjusted by varying extension times.
4. The recombination process can be carried out in a single tube.
- 30 5. The process can be carried out on single-stranded or double-stranded polynucleotides.
6. The process avoids the bias introduced by DNase I or other endonucleases.
7. Universal primers can be used.
- 35 8. Defined primers exhibiting limited randomness can be used to increase the frequency of mutation at selected areas of the gene.

As will be appreciated by those skilled in the art, several embodiments of the present invention are possible. Exemplary embodiments include:

1. Recombination and point mutation of related genes using only defined flanking primers and staggered extension.
2. Recombination and mutation of related genes using flanking primers and a series of internal primers at low enough concentration that exhaustion of the primers will occur over the course of the thermocycling, forcing the overlapping gene fragments to cross-hybridize and extend until recombined synthetic genes are formed.
3. Recombination and mutation of genes using random-sequence primers at high concentration to generate a pool of short DNA fragments which are reassembled to form new genes.
4. Recombination and mutation of genes using a set of defined primers to generate a pool of DNA fragments which are reassembled to form new genes.
5. Recombination and mutation of single-stranded polynucleotides using one or more defined primers and staggered extension to form new genes.
6. Recombination using defined primers with limited randomness at more than 30% or more than 60% of the nucleotide positions within the primer.

Examples of practice showing use of the primer-based recombination method are as follows.

EXAMPLE 1

Use of defined flanking primers and staggered extension to recombine and enhance the thermostability of subtilisin E

This example shows how the defined primer recombination method can be used to enhance the thermostability of subtilisin E by recombination of two genes known to encode subtilisin E variants with thermostabilities exceeding that of wild-type subtilisin E. This example demonstrates the general method outlined in FIG. 3 utilizing only two primers corresponding to the 5' and 3' ends of the templates.

As outlined in FIG. 3, extended recombination primers are first generated by the staggered extension process (StEP), which consists of repeated cycles of denaturation followed by extremely abbreviated annealing/extension step(s). The extended fragments are reassembled into full-length genes by thermocycling-assisted homologous gene assembly in the

presence of a DNA polymerase, followed by an optional gene amplification step.

Two thermostable subtilisin E mutants R1 and R2 were used to test the defined primer based recombination technique using staggered extension.

5 The positions at which these two genes differ from one another are shown in Table 1. Among the ten nucleotide positions that differ in R1 and R2, only those mutations leading to amino acid substitutions Asn 181-Asp (N181D) and Asn 218-Ser (N218S) confer thermostability. The remaining mutations are neutral with respect to their effects on thermostability (33). The half-lives at
10 65°C of the single variants N181D and N218S are approximately 3-fold and 2-fold greater than that of wild type subtilisin E, respectively, and their melting temperatures, T_m , are 3.7°C and 3.2°C higher than that of wild type enzyme, respectively. Random recombination events that yield sequences containing both these functional mutations will give rise to enzymes whose half lives at
15 65°C are approximately 8-fold greater than that of wild type subtilisin E, provided no new deleterious mutations are introduced into these genes during the recombination process. Furthermore, the overall point mutagenesis rate associated with the recombination process can be estimated from the catalytic activity profile of a small sampling of the recombined variant library. If the
20 point mutagenesis rate is zero, 25% of the population should exhibit wild type-like activity, 25% of the population should have double mutant (N181D+N218S)-like activity and the remaining 50% should have single mutant (N181D or N218S)-like activity. Finite point mutagenesis increases the fraction of the library that encodes enzymes with wild-type like (or lower)
25 activity. This fraction can be used to estimate the point mutagenesis rate.

TABLE 1
DNA and amino acid substitutions in thermostable
subtilisin E mutants R1 and R2.

Gene	Base	Base Substitution	Position in codon	Amino acid	Amino acid substitution
R1	780	A → G	2	109	Asn→Ser
	1107	A → G	2	218	Asn→Ser
	1141	A → T	3	229	synonymous
	1153	A → G	3	233	synonymous
R2	484	A → G	3	10	synonymous
	520	A → T	3	22	synonymous
	598	A → G	3	48	synonymous
	731	G → A	1	93	Val→Ile
	745	T → C	3	97	synonymous
	780	A → G	2	109	Asn→Ser
	995	A → G	1	181	Asn→Asp
	1189	A → G	3	245	synonymous

Mutations listed are relative to wild type subtilisin E with base substitution at 780 in common.

5

Materials and Methods

Procedure for defined primer based recombination using two flanking primers.

Two defined primers, P5N (5'-CCGAG CGTTG CATAT GTGGA AG-3' (SEQ. ID. NO: 1), underlined sequence is NdeI restriction site) and P3B (5'-CGACT CTAGA GGATC CGATT C-3' (SEQ. ID. NO: 2), underlined sequence is BamHI restriction site), corresponding to 5' and 3' flanking primers, respectively, were used for recombination. Conditions (100 ul final volume): 0.15 pmol plasmid DNA containing genes R1 and R2 (mixed at 1:1) were used as template, 15 pmol of each flanking primer, 1 times *Taq* buffer, 0.2 mM of each dNTP, 1.5 mM MgCl₂ and 0.25 U *Taq* polymerase. Program: 5' minutes of 95°C, 80 cycles of 30 seconds 94°C, 5 seconds 55°C. The product of correct size (approximately 1kb) was cut from an 0.8% agarose gel after electrophoresis and purified using QIAEX II gel extraction kit. This purified product was digested with NdeI and BamHI and subcloned into pBE3 shuttle vector. This gene library was amplified in *E. coli* HB101 and transferred into *B. subtilis* DB428 competent cells for expression and screening, as described elsewhere (35).

25 DNA sequencing

Genes were purified using QIAprep spin plasmid miniprep kit to obtain sequencing quality DNA. Sequencing was done on an ABI 373 DNA

Sequencing System using the Dye Terminator Cycle Sequencing kit (Perkin-Elmer, Branchburg, NJ).

Results

5 The progress of the staggered extension was monitored by removing aliquots (10 ul) from the reaction tube at various time points in the primer extension process and separating DNA fragments by agarose gel electrophoresis. Gel electrophoresis of primer extension reactions revealed that annealing/extension reactions of 5 seconds at 55°C resulted in the
10 occurrence of a smear approaching 100 bp (after 20 cycles), 400 bp (after 40 cycles), 800 bp (after 60 cycles) and finally a strong approximately 1 kb band within this smear. This band (mixture of reassembled products) was gel purified, digested with restriction enzyme *Bam*HI and *Nde*I, and ligated with
15 vector generated by *Bam*HI-*Nde*I digestion of the *E. coli* / *B. subtilis* pBE3 shuttle vector. This gene library was amplified in *E. coli* HB101 and transferred into *B. subtilis* DB428 competent cells for expression and screening (35).

 The thermostability of enzyme variants was determined in the 96-well plate format described previously (33). About 200 clones were screened, and
20 approximately 25% retained subtilisin activity. Among these active clones, the frequency of the double mutant-like phenotype (high thermostability) was approximately 23%, the single mutant-like phenotype was approximately 42%, and wild type-like phenotype was approximately 34%. This distribution is very close to the values expected when the two thermostable mutations N218S
25 and N181D can recombine with each other completely freely.

 Twenty clones were randomly picked from *E. coli* HB101 gene library. Their plasmid DNAs were isolated and digested with *Nde*I and *Bam*HI. Nine
30 out of 20 (45%) had the inserts of correct size (approximately 1 kb). Thus, approximately 55% of the above library had no activity due to lack of the correct subtilisin E gene. These clones are not members of the subtilisin library and should be removed from our calculations. Taking into account this factor, we find that 55% of the library (25% active clones/45% clones with correct size insert) retained subtilisin activity. This activity profile indicates a point mutagenesis rate of less than 2 mutations per gene (36). Five clones with
35 inserts of the correct size were sequenced. The results are summarized in FIG. 4. All five genes are recombination products with minimum crossovers

pronounced smear is evident extending from 0.5 kb to 4 kb, and exhibiting maximal signal intensity at a size of approximately 2 kb (the length of the full length genes). The jump from half-length to full length genes appears to occur between cycles 60 and 70.

5 The intense smear is amplified through 6 cycles of polymerase chain reaction to more clearly define the full length recombined gene population. A minus-primer control is also amplified with flanking primers to determine the background due to residual template in the reaction mix. Band intensity from the primer extended gene population exceeds that of the control by greater
10 than 10-fold, indicating that amplified, non-recombined template comprise only a small fraction of the amplified gene population.

 The amplified recombined gene pool is digested with restriction enzymes XbaI and BamHI and ligated into the pNB106R expression vector described by Zock et al. (35). Transformation of ligated DNA into E. coli strain
15 TG1 is done using the well characterized calcium chloride transformation procedure. Transformed colonies are selected on LB/agar plates containing 20 µg/ml tetracycline.

 The mutagenic rate of the process is determined by measuring the percent of clones expressing an active esterase (20). In addition, colonies
20 picked at random are sequenced and used to define the mutagenic frequency of the method and the efficiency of recombination.

EXAMPLE 3

Recombination of pNB esterase genes using interspersed 25 internal defined primers and staggered extension

 This example demonstrates that the interspersed defined primer recombination technique can produce novel sequences through point mutagenesis and recombination of mutations present in the parent sequences.

30 Experimental design and background information

 Two pNB esterase genes (2-13 and 5-B12) were recombined using the defined primer recombination technique. Gene products from both 2-13 and 5-B12 are measurably more thermostable than wild-type. Gene 2-13 contains 9 mutations not originally present in, the wild-type sequence, while gene 5-
35 B12 contains 14. The positions at which these two genes differ from one another are shown in FIG. 5.

Table 3 shows the sequences of the eight primers used in this example. Location (at the 5' end of the template gene) of oligo annealing to the template genes is indicated in the table, as is primer orientation (F indicates a forward primer, R indicates reverse). These primers are shown as arrows along gene 2-13 in FIG. 5.

TABLE 3

Sequences of primers used in this example

name	orientation	location	sequence
RM1A	F	-76	GAGCACATCAGATCTATTAAC (SEQ. ID. NO: 3)
RM2A	R	+454	GGAGTGGCTCACAGTCGGTGG (SEQ. ID. NO: 4)
S2	F	400	TTGAACTATCGGCTGGGGCGG (SEQ. ID. NO: 5)
S5	F	1000	TTACTAGGGAAGCCGCTGGCA (SEQ. ID. NO: 6)
S7	F	1400	TCAGAGATTACGATCGAAAAC (SEQ. ID. NO: 7)
S8	R	1280	GGATTGTATCGTGTGAGAAAG (SEQ. ID. NO: 8)
S10	R	880	AATGCCGGAAGCAGCCCCTTC (SEQ. ID. NO: 9)
S13	R	280	CACGACAGGAAGATTTTGA (SEQ. ID. NO: 10)

Materials and Methods

Defined-primer based recombination

1. Preparation of genes to be recombined. Plasmids containing the genes to be recombined were purified from transformed TG1 cells using the Qiaprep kit (Qiagen, Chatsworth, CA). Plasmids were quantitated by UV absorption and mixed 1:1 for a final concentration of 50 ng/ul.

2. Staggered extension PCR and reassembly. 4 μ l of the plasmid mixture was used as template in a 100 μ l standard reaction (1.5 mM MgCl₂, 50 mM KCl, 10 mM Tris-HCl pH 9.0, 0.1% Triton X-100, 0.2 mM dNTPs, 0.25 U Taq polymerase (Promega, Madison, WI)) which also contained 12.5 ng of each of the 8 primers. A control reaction which contained no primers was also assembled. Reactions were thermocycled through 100 cycles of 94°C, 30 seconds; 55°C, 15 seconds. Checking an aliquot of the reaction on an agarose gel at this point showed the product to be a large smear (with no visible product in the no primer control).

3. DpnI digestion of the templates. 1 μ l from the assembly reactions was then digested with DpnI to remove the template plasmid. The 10 μ l DpnI digest contained 1 x NEBuffer 4 and 5 U DpnI (both obtained from

New England Biolabs, Beverly, MA) and was incubated at 37°C for 45 minutes, followed by incubation at 70°C for 10 minutes to heat kill the enzyme.

4. PCR amplification of the reassembled products. The 10 µl digest was then added to 90 µl of a standard PCR reaction (as described in step 2) containing 0.4 µM primers 5b (ACTTAATCTAGAGGGTATTA) (SEQ. ID. NO: 11) and 3b (AGCCTCGCGGGATCCCCGGG) (SEQ. ID. NO: 12) specific for the ends of the gene. After 20 cycles of standard PCR (94°C, 30 seconds; 48°C, 30 seconds, 72°C, 1 minute) a strong band of the correct size (2 kb) was visible when the reaction was checked on an agarose gel, while only a very faint band was visible in the lane from the no-primer control. The product band was purified and cloned back into the expression plasmid pNB106R and transformed by electroporation into TG1 cells.

Results

Four 96 well plates of colonies resulting from this transformation were assayed for pNB esterase initial activity and thermostability. Approximately 60% of the clones exhibited initial activity and thermostability within 20% of the parental gene values. Very few (10%) of the clones were inactive (less than 10% of parent initial activity values). These results suggest a low rate of mutagenesis. Four mutants with the highest thermostability values were sequenced. Two clones (6E6 and 6H1) were the result of recombination between the parental genes (FIG. 5). One of the remaining two clones contained a novel point mutation, and one showed no difference from parent 5B12. The combination of mutations T99C and C204T in mutant 6E6 is evidence for a recombination event between these two sites. In addition, mutant 6H1 shows the loss of mutation A1072G (but the retention of mutations C1038T and T1310C), which is evidence for two recombination events (one between sites 1028 and 1072, and another between 1072 and 1310). A total of five new point mutations were found in the four genes sequenced.

EXAMPLE 4

Recombination of two thermostable subtilisin E variants using internal defined primers and staggered extension

This example demonstrates that the defined primer recombination technique can produce novel sequences containing new combinations of mutations present in the parent sequences. It further demonstrates the utility of the defined primer recombination technique to obtain further improvements

in enzyme performance (here, thermostability). This example further shows that the defined primers can bias the recombination so that recombination appears most often in the portion of the sequence defined by the primers (inside the primers). Furthermore, this example shows that specific mutations can be introduced into the recombined sequences by using the appropriate defined primer sequence(s) containing the desired mutation(s).

Genes encoding two thermostable subtilisin E variants of Example 1 (R1 and R2) were recombined using the defined primer recombination procedure with internal primers. FIG. 6 shows the four defined internal primers used to generate recombined progeny genes from template genes R1 and R2 in this example. Primer P50F contains a mutation (A→T at base position 598) which eliminates a HindIII restriction site and simultaneously adds a new unique NheI site. This primer is used to demonstrate that specific mutations can also be introduced into the population of recombined sequences by specific design of the defined primer. Gene R2 also contains a mutation A→G at the same base position, which eliminates the HindIII site. Thus restriction analysis (cutting by NheI and HindIII) of random clones sampled from the recombined library will indicate the efficiency of recombination and of the introduction of a specific mutation via the mutagenic primer. Sequence analysis of randomly-picked (unscreened) clones provides further information on the recombination and mutagenesis events occurring during defined primer-based recombination.

Materials and Methods

Defined-primer based recombination

A version of the defined primer based recombination illustrated in FIG. 2 was carried out with the addition of StEP.

1. Preparation of genes to be recombined. About 10 ug of plasmids containing R1 and R2 gene were digested at 37°C for 1 hour with *NdeI* and *BamHI* (30 U each) in 50 µl of 1x buffer B (Boehringer Mannheim, Indianapolis, IN). Inserts of approximately 1 kb were purified from 0.8% preparative agarose gels using QIAEX II gel extraction kit. The DNA inserts were dissolved in 10 mM Tris-HCl (pH 7.4). The DNA concentrations were estimated, and the inserts were mixed 1:1 for a concentration of 50 ng/ul.

2. Staggered extension PCR and reassembly. Conditions (100 ul final volume): about 100 ng inserts were used as template, 50 ng of each of 4 internal primers, 1x Taq buffer, 0.2 mM of each dNTP, 1.5 mM MgCl₂ and 25 U Taq polymerase. Program: 7 cycles of 30 seconds at 94°C, 15 seconds at

55°C, followed by another 10 cycles of 30 seconds at 94°C, 15 seconds at 55°C, 5 seconds at 72°C (staggered extension), followed by 53 cycles of 30 seconds at 94°C, 15 seconds at 55°C, 1 minute at 72°C (gene assembly).

3. *DpnI* digestion of the templates. 1 µl of this reaction was diluted up to 9.5 µl with dH₂O and 0.5 µl of *DpnI* restriction enzyme was added to digest the DNA template for 45 minutes, followed by incubation at 70°C for 10 minutes and then this 10 µl was used as template in a 10-cycle PCR reaction.

4. PCR amplification of reassembled products. PCR conditions (100 µl final volume): 30 pmol of each outside primer P5N and P3B, 1x Taq buffer, 0.2 mM of each dNTP and 2.5 U of Taq polymerase. PCR program: 10 cycles of 30 seconds at 94°C, 30 seconds at 55°C, 1 minute at 72°C. This program gave a single band at the correct size. The product was purified and subcloned into pBE3 shuttle vector. This gene library was amplified in *E. coli* HB101 and transferred into *B. subtilis* DB428 competent cells for expression and screening, as described elsewhere (35). Thermostability of enzyme variants was determined in the 96-well plate format described previously (33).

DNA sequencing

Ten *E. coli* HB101 transformants were chosen for sequencing. Genes were purified using QIAprep spin plasmid miniprep kit to obtain sequencing quality DNA. Sequencing was done on an ABI 373 DNA Sequencing System using the Dye Terminator Cycle Sequencing kit (Perkin-Elmer, Branchburg, NJ).

Results

1) restriction analysis:

Forty clones randomly picked from the recombined library were digested with restriction enzymes *NheI* and *BamHI*. In a separate experiment the same forty plasmids were digested with *HindIII* and *BamHI*. These reaction products were analyzed by gel electrophoresis. As shown in FIG. 7, eight out of 40 clones (approximately 20%) contain the newly introduced *NheI* restriction site, demonstrating that the mutagenic primer has indeed been able to introduce the specified mutation into the population.

2) DNA sequence analysis

The first ten randomly picked clones were subjected to sequence analysis, and the results are summarized in FIG. 8. A minimum of 6 out of the 10 genes have undergone recombination. Among these 6 genes, the minimal crossover events (recombination) between genes R1 and R2 vary from

1 to 4. All visible crossovers occurred within the region defined by the four primers. Mutations outside this region are rarely, if ever, recombined, as shown by the fact that there is no recombination between the two mutations at base positions 484 and 520. These results show that the defined primers can bias recombination so that it appears most often in the portion of the sequence defined by the primers (inside the primers). Mutations very close together also tend to remain together (for example, base substitutions 731 and 745 and base substitutions 1141 and 1153 always remain as a pair). However, the sequence of clone 7 shows that two mutations as close as 33 bases apart can be recombined (base position at 1107 and 1141).

Twenty-three new point mutations were introduced in the ten genes during the process. This error rate of 0.23% corresponds to 2-3 new point mutations per gene, which is a rate that has been determined optimal for generating mutant libraries for directed enzyme evolution (15). The mutation types are listed in Table 4. Mutations are mainly transitions and are evenly distributed along the gene.

TABLE 4

New point mutations identified in ten recombined genes

Transition	Frequency	Transversion	Frequency
G → A	4	A → T	1
A → G	4	A → C	1
C → T	3	C → A	1
T → C	5	C → G	0
		G → C	1
		G → T	0
		T → A	3
		T → G	0

A total of 9860 bases were sequenced. The mutation rate was 0.23%

4) Phenotypic analysis

Approximately 450 *B. subtilis* DB428 clones were picked and grown in SG medium supplemented with 20 ug/ml kanamycin in 96-well plates. Approximately 56% of the clones expressed active enzymes. From previous experience, we know that this level of inactivation indicates a mutation rate on the order of 2-3 mutations per gene (35). Approximately 5% clones showed

double mutant (N181D+N218S)-like phenotypes (which is below the expected 25% value for random recombination alone due primarily to point mutagenesis). (DNA sequencing showed that two clones, 7 and 8, from the ten randomly picked clones contain both N218S and N181D mutations.)

5

EXAMPLE 5

Optimization of the *Actinoplanes utahensis* ECB deacylase by the random-priming recombination method

In this example, the method is used to generate short DNA fragments from denatured, linear, double-stranded DNA (e.g., restriction fragments purified by gel electrophoresis; 22). The purified DNA, mixed with a molar excess of primers, is denatured by boiling, and synthesis is then carried out using the Klenow fragment of *E. coli* DNA polymerase I. This enzyme lacks 5'→3' exonuclease activity, so that the random priming product is synthesized exclusively by primer extension and is not degraded by exonuclease. The reaction is carried out at pH 6.6, where the 3'→5' exonuclease activity of the enzyme is much reduced (36). These conditions favor random initiation of synthesis.

15

The procedure involves the following steps:

20

1. Cleave the DNA of interest with appropriate restriction endonuclease(s) and purify the DNA fragment of interest by gel electrophoresis using Wizard PCR Prep Kit (Promega, Madison, WI). As an example, the *Actinoplanes utahensis* ECB deacylase gene was cleaved as a 2.4 kb-long *Xho*I-*Psh*AI fragment from the recombinant plasmid pSHP100. It was essential to linearize the DNA for the subsequent denaturation step. The fragment was purified by agarose gel electrophoresis using the Wizard PCR Prep Kit (Promega, Madison, WI) (FIG.9, step (a)). Gel purification was also essential in order to remove the restriction endonuclease buffer from the DNA, since the Mg^{2+} ions make it difficult to denature the DNA in the next step.

25

2. 400 ng (about 0.51 pmol) of the double-stranded DNA dissolved in H_2O was mixed with 2.75 μg (about 1.39 nmol) of dp(N)₆ random primers. After immersion in boiling water for 3 minutes, the mixture was placed immediately in an ice/ethanol bath.

30

The size of the random priming products is an inverse function of the concentration of primer (33). The presence of high concentrations of primer is thought to lead to steric hindrance. Under the reaction conditions described

35

here the random priming products are approximately 200-400 bp, as determined by electrophoresis through an alkaline agarose gel (FIG. 9 step b).

3. Ten μ l of 10 x reaction buffer [10X buffer: 900 mM HEPES, pH 6.6; 0.1 M magnesium chloride, 10 mM dithiothreitol, and 5 mM each dATP, dCTP, dGTP and dTTP] was added to the denatured sample, and the total volume of the reaction mixture was brought up to 95 μ l with H₂O.

4. Ten units (about 5 μ l) of the Klenow fragment of *E.coli* DNA polymerase I was added. All the components were mixed by gently tapping the outside of the tube and were centrifuged at 12,000 g for 1-2 seconds in a microfuge to move all the liquid to the bottom. The reaction was carried out at 22°C for 35 minutes.

The rate of the extension depends upon the concentrations of the template and the four nucleotide precursors. Because the reaction was carried out under conditions that minimize exonucleolytic digestion, the newly synthesized products were not degraded to a detectable extent.

5. After 35 minutes at 22°C, the reaction was terminated by cooling the sample to 0°C on ice. 100 μ l of ice-cold H₂O was added to the reaction mixture.

6. The random primed products were purified by passing the whole reaction mixture through Centricon-100 (to remove the template and proteins) and Centricon-10 filters (to remove the primers and fragments less than 50 bases), successively. Centricon filters are available from Amicon Inc (Beverly, MA). The retentate fraction (about 85 μ l in volume) was recovered from Centricon-10. This fraction contained the desired random priming products (FIG. 9, step c) and was used for whole gene reassembly.

Reassembly of the whole gene was accomplished by the following steps:

1. For reassembly by PCR, 5 μ l of the random-primed DNA fragments from Centricon-10, 20 μ l of 2x PCR pre-mix (5-fold diluted cloned *Pfu* buffer, 0.5 mM each dNTP, 0.1U/ μ l cloned *Pfu* polymerase (Stratagene, La Jolla, CA)), 8 μ l of 30% (v/v) glycerol and 7 μ l of H₂O were mixed on ice. Since the concentration of the random-primed DNA fragments used for reassembly is the most important variable, it is useful to set up several separate reactions with different concentrations to establish the preferred concentration.

2. After incubation at 96°C for 6 minutes, 40 thermocycles were performed, each with 1.5 minutes at 95°C, 1.0 minutes at 55°C and 1.5 minutes + 5 second/cycle at 72°C, with the extension step of the last cycle

proceeding at 72°C for 10 minutes, in a DNA Engine PTC-200 (MJ Research Inc., Watertown, MA) apparatus without adding any mineral oil.

3. 3 µl aliquots at cycles 20, 30 and 40 were removed from the reaction mixture and analyzed by agarose gel electrophoresis. The reassembled PCR product at 40 cycles contained the correct size product in a smear of larger and smaller sizes (see FIG. 9, step d).

The correctly reassembled product of this first PCR was further amplified in a second PCR reaction which contained the PCR primers complementary to the ends of the template DNA. The amplification procedure was as follows:

1. 2.0 µl of the PCR reassembly aliquots were used as template in 100-µl standard PCR reactions, which contained 0.2 mM each primers of *xho*F28 (5' GG TAGAGCGAGTCTCGAGGGGGAGATGC3') (SEQ. ID. NO: 13) and *psh*R22 (5' AGCCGGCGTGACGTGGGTCAGC 3') (SEQ. ID. NO: 14), 1.5 mM MgCl₂, 10 mM Tris-HCl [pH 9.0], 50 mM KCl, 200 µM each of the four dNTPs, 6% (v/v) glycerol, 2.5 U of *Taq* polymerase (Promega, Madison, WI) and 2.5 U of *Pfu* polymerase (Stratagene, La Jolla, CA).

2. After incubation at 96°C for 5 minutes, 15 thermocycles were performed, each with 1.5 minutes at 95°C, 1.0 minutes at 55°C and 1.5 minutes at 72°C, followed by additional 15 thermocycles of 1.5 minutes at 95°C, 1.0 minutes at 55°C and 1.5 minutes + 5 second/cycle at 72°C with the extension step of the last cycle proceeding at 72°C for 10 minutes, in a DNA Engine PTC-200 (MJ Research Inc., Watertown, MA) apparatus without adding any mineral oil.

3. The amplification resulted in a large amount of PCR product with the correct size of the ECB deacylase whole gene (FIG. 9, step e).

Cloning was accomplished as follows:

1. The PCR product of ECB deacylase gene was digested with *Xho* I and *Psh* AI restriction enzymes, and cloned into a modified pIJ702 vector.

2. *S. lividans* TK23 protoplasts were transformed with the above ligation mixture to form a mutant library.

In situ screening the ECB deacylase mutants

Each transformant within the *S. lividans* TK23 library obtained as described above was screened for deacylase activity with an *in situ* plate assay

method using ECB as substrate. Transformed protoplasts were allowed to regenerate on R2YE agar plates by incubation at 30°C for 24 hours and to develop in the presence of thiostrepton for further 48-72 hours. When the colonies grew to proper size, 6 ml of 45°C purified-agarose (Sigma) solution containing 0.5 mg/ml ECB in 0.1 M sodium acetate buffer (pH 5.5) was poured on top of each R2YE-agar plate and allowed to further develop for 18-24 hours at 37°C. Colonies surrounded by a clearing zone larger than that of a control colony containing wild-type recombinant plasmid pSHP150-2 were indicative of more efficient ECB hydrolysis resulting from improved enzyme properties or improved enzyme expression and secretion level, and were chosen as potential positive mutants. These colonies were picked for subsequent preservation and manipulation.

HPLC assay of the ECB deacylase mutants

Single positive transformants were inoculated into 20 ml fermentation medium containing 5 µg/ml thiostrepton and allowed to grow at 30°C for 48 hours. At this step, all cultures were subjected to HPLC assay using ECB as substrate. 100 µl of whole broth was used for an HPLC reaction at 30°C for 30 minutes in the presence of 0.1 M NaAc (pH 5.5), 10% (v/v) MeOH and 200 µg/ml of ECB substrate. 20 µl of each reaction mixture was loaded onto a PolyLC polyhydroxyethyl aspartamide column (4.6 x 100 mm) and eluted by acetonitrile gradient at a flow rate of 2.2 ml/min. The ECB-nucleus was detected at 225 nm.

Purification of the ECB deacylase mutants

After the HPLC assay, 2.0 ml pre-cultures of all potential positive mutants were then used to inoculate 50-ml fermentation medium and allowed to grow at 30°C, 280 rpm for 96 hours. These 50-ml cultures were then centrifuged at 7,000 g for 10 minutes. The supernatants were re-centrifuged at 16,000 g for 20 minutes. The supernatants containing the ECB deacylase mutant enzymes were stored at -20°C.

The supernatants from the positive mutants were further concentrated to 1/30 their original volume with an Amicon filtration unit with molecular weight cutoff of 10 kD. The resulting enzyme samples were diluted with an equal volume of 50 mM KH₂PO₄ (pH 6.0) buffer and 1.0 ml was applied to Hi-Trap ion exchange column. The binding buffer was 50 mM KH₂PO₄ (pH 6.0), and the elution buffer was 50 mM KH₂PO₄ (pH 6.0) and 1.0 M NaCl. A linear

gradient from 0 to 1.0 M NaCl was applied in 8 column volumes with a flow rate of 2.7 ml/min. The ECB deacylase mutant fraction eluted at 0.3 M NaCl and was concentrated and buffer exchanged into 50 mM KH₂PO₄ (pH 6.0) in Amicon Centricon-10 units. Enzyme purity was verified by SDS-PAGE, and the concentration was determined using the Bio-Rad Protein Assay.

Specific activity assay of the ECB deacylase mutants

4.0 µg of each purified ECB deacylase mutant was used for the activity assay at 30°C for 0-60 minutes in the presence of 0.1 M NaAc (pH 5.5), 10% (v/v) MeOH and 200 µg/ml of ECB substrate. 20 µl of each reaction mixture was loaded onto a PolyLC polyhydroxyethyl aspartamide column (4.6 x 100 mm) and eluted with an acetonitrile gradient at a flow rate of 2.2 ml/min. The reaction products were monitored at 225 nm and recorded on an IBM PC data acquisition system. The ECB nucleus peak was numerically integrated and used to calculate the specific activity of each mutant.

As shown in FIG. 10, after only one round of applying this random-priming based technique on the wild-type ECB deacylase gene, one mutant (M16) from 2,012 original transformants was found to possess 2.4 times the specific activity of the wild-type enzyme. FIG 11 shows that the activity of M16 has been increased relative to that of the wild-type enzyme over a broad pH range.

The nucleotide sequence which encodes the M16 mutant gene is set forth in SEQ. ID. NO: 26. The nucleotide sequence for the wild-type ECB deacylase gene is set forth in SEQ. ID. NO: 31.

Other mutant genes which were isolated utilizing the above method include mutant M2#7, M2#14, M15 and M20. The nucleotide sequences for these mutant genes are set forth in SEQ. ID. NOS: 27, 28, 29 and 30, respectively. The amino acid sequences for the ECB deacylases encoded by the mutant genes are set forth in SEQ. ID. NOS: 32 (M16); 33 (M2#7); 34 (M2#14); 35 (M15); and 36 (M20).

The above-identified mutant genes may be ligated into a suitable expression vector and incorporated into a host cell or organism for expression.

The resulting ECB deacylase enzyme which is expressed by the transformed host cell or organism may be isolated, purified and used as an enzyme in a wild variety of synthetic protocols which require the ECB deacylase enzyme. Alternatively, the transformed host cell or organism may be incorporated

directly into suitable production broths where the ECB deacylase enzyme is generated *in situ* by the transformant.

EXAMPLE 6

5 **Improving the thermostability *Bacillus subtilis* subtilisin E
 using the random-sequence primer recombination method**

This example demonstrates the use of various DNA polymerases for primer-based recombination. It further demonstrates the stabilization of subtilisin E by recombination.

10 Genes R1 and R2 encoding the two thermostable subtilisin E variants described in Example 1 were chosen as the templates for recombination.

(1) *Target gene preparation*

15 Subtilisin E thermostable mutant genes R1 and R2 (FIG.11) were subjected to random primed DNA synthesis. The 986-bp fragment including 45 nt of subtilisin E prosequence, the entire mature sequence and 113 nt after the stop codon were obtained by double digestion of plasmid pBE3 with *Bam* HI and *Nde* I and purified from a 0.8% agarose gel using the Wizard PCR Prep Kit (Promega, Madison, WI). It was essential to linearize the DNA for the
20 subsequent denaturation step. Gel purification was also essential in order to remove the restriction endonuclease buffer from the DNA, since the Mg^{2+} ions make it difficult to denature the DNA in the next step.

(2) *Random primed DNA synthesis*

25 Random primed DNA synthesis used to generate short DNA fragments from denatured, linear, double-stranded DNA. The purified *B. subtilis* subtilisin E mutant genes, mixed with a molar excess of primers, were denatured by boiling, and synthesis was then carried out using one of the following DNA polymerases: the Klenow fragment of *E. coli* DNA polymerase I, bacteriophage T4 DNA polymerase and T7 sequenase version 2.0 DNA
30 polymerase.

 Under its optimal performance conditions (29), bacteriophage T4 DNA polymerase gives similar synthesis results as the Klenow fragment does. When T7 sequenase version 2.0 DNA polymerase (31, 32) is used, the lengths of the
35 synthesized DNA fragments are usually larger. Some amount of $MnCl_2$ has to be included during the synthesis in order to control the lengths of the synthesized fragments within 50-400 bases.

Short, nascent DNA fragments can also be generated with PCR using the Stoffel fragment of *Taq* DNA polymerase or *Pfu* DNA polymerase. An important consideration is to identify by routine experimentation the reaction conditions which ensure that the short random primers can anneal to the templates and give sufficient DNA amplification at higher temperatures. We have found that random primers as short as dp(N)_{12} can be used with PCR to generate fragments.

2.1 Random primed DNA synthesis with the Klenow fragment

The Klenow fragment of *E. coli* DNA polymerase I lacks 5'→3' exonuclease activity, so that the random priming product is synthesized exclusively by primer extension and is not degraded by exonuclease. The reaction was carried out at pH 6.6, where the 3'→5' exonuclease activity of the enzyme is much reduced (36). These conditions favor random initiation of synthesis.

1. 200 ng (about 0.7 pmol) of R1 DNA and equal amount of R2 DNA dissolved in H₂O was mixed with 13.25 µg (about 6.7 nmol) of dp(N)_6 random primers. After immersion in boiling water for 5 minutes, the mixture was placed immediately in an ice/ethanol bath.

The size of the random priming products is an inverse function of the concentration of primer (30). The presence of high concentrations of primer is thought to lead to steric hindrance. Under the reaction conditions described here the random priming products are approximately 50-500 bp, as determined by agarose gel electrophoresis.

2. Ten µl of 10 x reaction buffer [10x buffer: 900 mM HEPES, pH 6.6; 0.1 M magnesium chloride, 20 mM dithiothreitol, and 5 mM each dATP, dCTP, dGTP and dTTP] was added to the denatured sample, and the total volume of the reaction mixture was brought up to 95 µl with H₂O.

3. Ten units (about 5 µl) of the Klenow fragment of *E. coli* DNA polymerase I (Boehringer Mannheim, Indianapolis, IN) was added. All the components were mixed by gently tapping the outside of the tube and were centrifuged at 12,000 g for 1-2 seconds in a microfuge to move all the liquid to the bottom. The reaction was carried out at 22°C for 3 hours.

The rate of the extension depends upon the concentrations of the template and the four nucleotide precursors. Because the reaction was carried out under conditions that minimize exonucleolytic digestion, the newly synthesized products were not degraded to a detectable extent.

4. After 3 hours at 22°C, the reaction was terminated by cooling the sample to 0°C on ice. 100 µl of ice-cold H₂O was added to the reaction mixture.

5. The random primed products were purified by passing the whole reaction mixture through Microcon-100 (Amicon, Beverly MA) (to remove the template and proteins) and Microcon-10 filters (to remove the primers and fragments less than 40 bases), successively. The retentate fraction (about 65 µl in volume) was recovered from the Microcon-10. This fraction containing the desired random priming products was buffer-exchanged against PCR reaction buffer with the new Microcon-10 further use in whole gene reassembly.

2.2 Random primed DNA synthesis with bacteriophage T4 DNA polymerase

Bacteriophage T4 DNA polymerase and the Klenow fragment of *E. coli* DNA polymerase I are similar in that each possesses a 5'-3' polymerase activity and a 3'-5' exonuclease activity. The exonucleases activity of bacteriophage T4 DNA polymerase is more than 200 times that of the Klenow fragment. Since it does not displace the short oligonucleotide primers from single-stranded DNA templates (23), the efficiency of mutagenesis is different from the Klenow fragment.

1. 200 ng (about 0.7 pmol) of R1 DNA and equal amount of R2 DNA dissolved in H₂O was mixed with 13.25 µg (about 6.7 nmol) of dp(N)₆ random primers. After immersion in boiling water for 5 minutes, the mixture was placed immediately in an ice/ethanol bath. The presence of high concentrations of primer is thought to lead to steric hindrance.

2. Ten µl of 10 x reaction buffer [10x buffer: 500 mM Tris-HCl, pH 8.8; 150 mM (NH₄)₂SO₄; 70 mM magnesium chloride, 100 mM 2-mercaptoethanol, 0.2 mg/ml bovine serum albumin and 2 mM each dATP, dCTP, dGTP and dTTP] was added to the denatured sample, and the total volume of the reaction mixture was brought up to 90 µl with H₂O.

3. Ten units (about 10 µl) of the T4 DNA polymerase I (Boehringer Mannheim, Indianapolis, IN) was added. All the components were mixed by gently tapping the outside of the tube and were centrifuged at 12,000 g for 1-2 seconds in a microfuge to move all the liquid to the bottom. The reaction was carried out at 37°C for 30 minutes. Under the reaction conditions described here the random priming products are approximately 50-500 bp.

4. After 30 minutes at 37°C, the reaction was terminated by cooling the sample to 0°C on ice. 100 µl of ice-cold H₂O was added to the reaction mixture.

5. The random primed products were purified by passing the whole reaction mixture through Microcon-100 (to remove the template and proteins) and Microcon-10 filters (to remove the primers and fragments less than 40 bases), successively. The retentate fraction (about 65 µl in volume) was recovered from the Microcon-10. This fraction containing the desired random priming products was buffer-exchanged against PCR reaction buffer with the new Microcon-10 further use in whole gene reassembly.

2.3 Random primed DNA synthesis with the T7 sequenase v2.0 DNA polymerase

Since the T7 sequenase v2.0 DNA polymerase lacks exonuclease activity and is highly processive, the average length of DNA synthesized is greater than that of DNAs synthesized by the Klenow fragment or T4 DNA polymerase. But in the presence of proper amount of MnCl₂ in the reaction, the size of the synthesized fragments can be controlled to less than 400 bps.

1. 200 ng (about 0.7 pmol) of R1 DNA and equal amount of R2 DNA dissolved in H₂O was mixed with 13.25 µg (about 6.7 nmol) of dp(N)₆ random primers. After immersion in boiling water for 5 minutes, the mixture was placed immediately in an ice/ethanol bath. The presence of high concentrations of primer is thought to lead to steric hindrance.

2. Ten µl of 10 x reaction buffer [10X buffer: 400 mM Tris-HCl, pH 7.5; 200 mM magnesium chloride, 500 mM NaCl, 3 mM MnCl₂, and 3 mM each dATP, dCTP, dGTP and dTTP) was added to the denatured sample, and the total volume of the reaction mixture was brought up to 99.2 µl with H₂O.

3. Ten units (about 0.8 µl) of the T7 Sequenase v2.0 (Amersham Life Science, Cleveland, Ohio) was added. All the components were mixed by gently tapping the outside of the tube and were centrifuged at 12,000 g for 1-2 seconds in a microfuge to move all the liquid to the bottom. The reaction was carried out at 22°C for 15 minutes. Under the reaction conditions described here the random priming products are approximately 50-400 bps.

4. After 15 minutes at 22°C, the reaction was terminated by cooling the sample to 0°C on ice. 100 µl of ice-cold H₂O was added to the reaction mixture.

5 5. The random primed products were purified by passing the whole reaction mixture through Microcon-100 (to remove the template and proteins) and Microcon-10 filters (to remove the primers and fragments less than 40 bases), successively. The retentate fraction (about 65 μ l in volume) was recovered from the Microcon-10. This fraction containing the desired random priming products was buffer-exchanged against PCR reaction buffer with the new Microcon-10 further use in whole gene reassembly.

10 2.4 Random primed DNA synthesis with PCR using the Stoffel fragment of *Taq* DNA polymerase

 Similar to the Klenow fragment of *E. coli* DNA polymerase I, the Stoffel fragment of *Taq* DNA polymerase lacks 5' to 3' exonuclease activity. It is also more thermostable than *Taq* DNA polymerase. The Stoffel fragment has low processivity, extending a primer an average of only 5-10 nucleotides before it dissociates. As a result of its lower processivity, it may also have improved fidelity.

15 1. 50 ng (about 0.175 pmol) of R1 DNA and equal amount of R2 DNA dissolved in H₂O was mixed with 6.13 μ g (about 1.7 nmol) of dp(N)₁₂ random primers.

20 2. Ten μ l of 10x reaction pre-mix [10x reaction pre-mix: 100 mM Tris-HCl, pH 8.3; 30 mM magnesium chloride, 100 mM KCl, and 2 mM each dATP, dCTP, dGTP and dTTP) was added, and the total volume of the reaction mixture was brought up to 99.0 μ l with H₂O.

25 3. After incubation at 96°C for 5 minutes, 2.5 units (about 1.0 μ l) of the Stoffel fragment of *Taq* DNA polymerase (Perkin-Elmer Corp., Norwalk, CT) was added. Thirty-five thermocycles were performed, each with 60 seconds at 95°C, 60 seconds at 55°C and 50 seconds at 72°C, without the extension step of the last cycle, in a DNA Engine PTC-200 (MJ Research Inc., Watertown, MA) apparatus. Under the reaction conditions described here the random priming products are approximately 50-500 bp.

30 4. The reaction was terminated by cooling the sample to 0°C on ice. 100 μ l of ice-cold H₂O was added to the reaction mixture.

35 5. The random primed products were purified by passing the whole reaction mixture through Microcon-100 (to remove the template and proteins) and Microcon-10 filters (to remove the primers and fragments less than 40 bases), successively. The retentate fraction (about 65 μ l in volume) was recovered from the Microcon-10. This fraction containing the desired random

priming products was buffer-exchanged against PCR reaction buffer with the new Microcon-10 further use in whole gene reassembly.

2.5 Random primed DNA synthesis with PCR using *Pfu* DNA polymerase

Pfu DNA polymerase is extremely thermostable, and the enzyme possesses an inherent 3' to 5' exonuclease activity but does not possess a 5'→3' exonuclease activity. Its base substitution fidelity has been estimated to be 2×10^{-6} .

1. 50 ng (about 0.175 pmol) of R1 DNA and equal amount of R2 DNA dissolved in H₂O was mixed with 6.13mg (about 1.7 nmol) of dp(N)₁₂ random primers.

2. Fifty µl of 2 x reaction pre-mix [2 x reaction pre-mix: 5-fold diluted cloned *Pfu* buffer (Stratagene, La Jolla, CA), 0.4 mM each dNTP], was added, and the total volume of the reaction mixture was brought up to 99.0 µl with H₂O.

3. After incubation at 96°C for 5 minutes, 2.5 units (about 1.0 µl) of *Pfu* DNA polymerase (Stratagene, La Jolla, CA) was added. Thirty-five thermocycles were performed, each with 60 seconds at 95°C, 60 seconds at 55°C and 50 seconds at 72°C, without the extension step of the last cycle, in a DNA Engine PTC-200 (MJ Research Inc., Watertown, MA) apparatus. Under the reaction conditions described here the major random priming products are approximately 50-500 bp.

4. The reaction was terminated by cooling the sample to 0°C on ice. 100 µl of ice-cold H₂O was added to the reaction mixture.

5. The random primed products were purified by passing the whole reaction mixture through Microcon-100 (to remove the template and proteins) and Microcon-10 filters (to remove the primers and fragments less than 40 bases), successively. The retentate fraction (about 65 µl in volume) was recovered from the Microcon-10. This fraction containing the desired random priming products was buffer-exchanged against PCR reaction buffer with the new Microcon-10 further use in whole gene reassembly.

(3) Reassembly of the whole gene

1. For reassembly by PCR, 10 µl of the random-primed DNA fragments from Microcon-10, 20 µl of 2 X PCR pre-mix (5-fold diluted cloned

Pfu buffer, 0.5 mM each dNTP, 0.1U/ μ l cloned *Pfu* polymerase (Stratagene, La Jolla, CA)), 15 μ l of H₂O were mixed on ice.

2. After incubation at 96°C for 3 minutes, 40 thermocycles were performed, each with 1.0 minute at 95°C, 1.0 minute at 55°C and 1.0 minute + 5 second/cycle at 72°C, with the extension step of the last cycle proceeding at 72°C for 10 minutes, in a DNA Engine PTC-200 (MJ Research Inc., Watertown, MA) apparatus without adding any mineral oil.

3. 3 μ l aliquots at cycles 20, 30 and 40 were removed from the reaction mixture and analyzed by agarose gel electrophoresis. The reassembled PCR product at 40 cycles contained the correct size product in a smear of larger and smaller sizes.

(4) Amplification

The correctly reassembled product of this first PCR was further amplified in a second PCR reaction which contained the PCR primers complementary to the ends of the template DNA.

1. 2.0 μ l of the PCR reassembly aliquots were used as template in 100- μ l standard PCR reactions, which contained 0.3 mM each primers of P1 (5' CCGAGCGTTGC ATATGTGGAAG 3') (SEQ. ID. NO: 15) and P2 (5' CGACTCTAGAGGATCCGATTC 3') (SEQ. ID. NO: 16), 1.5 mM MgCl₂, 10 mM Tris-HCl [pH 9.0], 50 mM KCl, 200 mM each of the four dNTPs, 2.5 U of *Taq* polymerase (Promega, Madison, WI, USA) and 2.5 U of *Pfu* polymerase (Stratagene, La Jolla, CA).

2. After incubation at 96°C for 3 minutes, 15 thermocycles were performed, each with 60 seconds at 95°C, 60 seconds at 55°C and 50 seconds at 72°C, followed by additional 15 thermocycles of 60 seconds at 95°C, 60 seconds at 55°C and 50 seconds (+ 5 second/cycle) at 72°C with the extension step of the last cycle proceeding at 72°C for 10 minutes, in a DNA Engine PTC-200 (MJ Research Inc., Watertown, MA) apparatus without adding any mineral oil.

3. The amplification resulted in a large amount of PCR product with the correct size of the subtilisin E whole gene.

(5) Cloning

Since the short DNA fragments were generated with five different DNA polymerases, there were five pools of final PCR amplified reassembled

products. Each of the DNA pool was used for constructing the corresponding subtilisin E mutant library.

5 1. The PCR amplified reassembled product was purified by Wizard DNA-CleanUp kit (Promega, Madison, WI), digested with *Bam* HI and *Nde* I, electrophoresed in a 0.8% agarose gel. The 986-bp product was cut from the gel and purified by Wizard PCR Prep kit (Promega, Madison, WI). Products were ligated with vector generated by *Bam* HI-*Nde* I digestion of the pBE3 shuttle vector.

10 2. *E. coli* HB101 competent cells were transformed with the above ligation mixture to form a mutant library. About 4,000 transformants from this library were pooled, and recombinant plasmid mixture was isolated from this pool.

15 3. *B. subtilis* DB428 competent cells were transformed with the above isolated plasmid mixture to form another library of the subtilisin E variants.

20 4. Based on the DNA polymerase used for random priming the short, nascent DNA fragments, the five libraries constructed here were named: library/Klenow, library/T4, library/Sequenase, library/Stoffel and library/Pfu. About 400 transformants from each library were randomly picked and subjected to screening for thermostability [see Step (7)].

(6) Random clone sequencing

25 Ten random clones from the *B. subtilis* DB428 library/Klenow was chosen for DNA sequence analysis. Recombinant plasmids were individually purified from *B. subtilis* DB428 using a QIAprep spin plasmid miniprep kit (QIAGEN) with the modification that 2 mg/ml lysozyme was added to P1 buffer and the cells were incubated for 5 minutes at 37°C, retransformed into competent *E. coli* HB 101 and then purified again using QIAprep spin plasmid miniprep kit to obtain sequencing quality DNA. Sequencing was done on an
30 ABI 373 DNA Sequencing System using the Dye Terminator Cycle Sequencing kit (Perkin-Elmer Corp., Norwalk, CT).

(7) Screening for thermostability

35 About 400 transformants from each of the five libraries described at Step (4) were subjected to screening. Screening was based on the assay described previously (33, 35), using succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (SEQ. ID. NO: 25) as substrate. *B. subtilis* DB428 containing the plasmid

library were grown on LB/kanamycin (20 µg/ml) plates. After 18 hours at 37°C single colonies were picked into 96-well plates containing 100 µl SG/kanamycin medium per well. These plates were shaken and incubated at 37°C for 24 hours to let the cells to grow to saturation. The cells were spun down, and the supernatants were sampled for the thermostability assay. Three replica 96-well assay plates were duplicated for each growth plate, with each well containing 10 ml of supernatant. The subtilisin activities were then measured by adding 100 µl of activity assay solution (0.2 mM succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (SEQ. ID. NO: 25), 100 mM Tris-HCl, 10 mM CaCl₂, pH 8.0, 37 °C). Reaction velocities were measured at 405 nm over 1.0 min. in a ThermoMax microplate reader (Molecular Devices, Sunnyvale CA). Activity measured at room temperature was used to calculate the fraction of active clones (clones with activity less than 10% of that of wild type were scored as inactive). Initial activity (Ai) was measured after incubating one assay plate at 65°C for 10 minutes by immediately adding 100 µl of prewarmed (37°C) assay solution (0.2mM succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (SEQ. ID. NO: 25), 100 mM Tris-HCl, pH 8.0, 10 mM CaCl₂) into each well. Residual activity (Ar) was measured after 40 minute incubation.

(8) Sequence Analysis

After screening, one clone that showed the highest thermostability within the 400 transformants from the library/Klenow was re-streaked on LB/kanamycin agar plate, and single colonies derived from this plate were inoculated into tube cultures, for glycerol stock and plasmid preparation. The recombinant plasmid was purified using a QIAprep spin plasmid miniprep kit (QIAGEN) with the modification that 2 mg/ml lysozyme was added to P1 buffer and the cells were incubated for 5 minutes at 37°C, retransformed into competent *E. coli* HB 101 and then purified again using QIAprep spin plasmid miniprep kit to obtain sequencing quality DNA. Sequencing was done on an ABI 373 DNA Sequencing System using the Dye Terminator Cycle Sequencing kit (Perkin-Elmer Corp., Norwalk, CT).

Results

1. Recombination frequency and efficiency associated with the random-sequence recombination.

The random primed process was carried out as described above. The process is illustrated in FIG. 1. Ten clones from the mutant library/Klenow were selected at random and sequenced. As summarized in FIG. 12 and Table

5, all clones were different from the parent genes. The frequency of occurrence of a particular point mutation from parent R1 or R2 in the recombined genes ranged from 40% to 70%, fluctuating around the expected value of 50%. This indicates that the two parent genes have been nearly randomly recombined with the random primer technique. FIG. 12 also shows that all ten mutations can be recombined or dissected, even those that are only 12 bp apart.

We then estimated the rates of subtilisin thermoinactivation at 65°C by analyzing the 400 random clones from each of the five libraries constructed at Step (5). The thermostabilities obtained from one 96-well plate are shown in FIG.13, plotted in descending order. Approximately 21% of the clones exhibited thermostability comparable to the mutant with the N181D and N218S double mutations. This indicates that the N181D mutation from RC2 and the N218S mutation from RC1 have been randomly recombined. Sequence analysis of the clone exhibiting the highest thermostability among the screened 400 transformants from the library/Klenow showed the mutation N181D and N218S did exist.

2. Frequency of newly introduced mutations during the random priming process.

Approximately 400 transformants from each of the five *B.subtilis* DB428 libraries [see Step (5)] were picked, grown in SG medium supplemented with 20 ug/ml kanamycin in 96-well plates and subjected to subtilisin E activity screening. Approximately 77-84% of the clones expressed active enzymes, while 16-23% of the transformants were inactive, presumably as a result of newly introduced mutations. From previous experience, we know that this rate of inactivation indicates a mutation rate on the order of 1 to 2 mutations per gene (35).

As shown in FIG. 12, 18 new point mutations were introduced in the process. This error rate of 0.18% corresponds to 1-2 new point mutations per gene, which is a rate that has been determined from the inactivation curve. Mutations are nearly randomly distributed along the gene.

TABLE 5
DNA and amino acid residue substitutions in the ten random clones from Library/Klenow

Clone #	Position	Base Substitution	Substitution Type	Amino Acid Substitution	Substitution Type
C#1	839	A→C	transversion	Gly→Gly	synonymous
C#2	722	A→G	transition	Ser→Ser	synonymous
C#2	902	T→C	transition	Val→Val	synonymous
C#2	1117	C→G	transversion	Ser→Ser	synonymous
C#4	809	T→C	transition	Asn→Asn	synonymous
C#4	1098	G→C	transversion	Gly→Ala	non-synonymous
C#4	1102	T→C	transition	Ala→Ala	synonymous
C#6	653	C→A	transversion	His→Ile	non-synonymous
C#6	654	A→T	transversion	His→Ile	non-synonymous
C#6	657	T→C	transition	Val→Ala	non-synonymous
C#6	658	A→C	transversion	Val→Ala	non-synonymous
C#6	1144	A→G	transition	Ala→Ala	synonymous
C#6	1147	A→G	transition	Ala→Ala	synonymous
C#7	478	T→C	transition	Ile→Ile	synonymous
C#9	731	A→G	transition	Ala→Ala	synonymous
C#9	994	A→G	transition	Val→Val	synonymous
C#10	1111	A→G	transition	Gly→Gly	synonymous
C#10	1112	A→T	transversion	Thr→Ser	non-synonymous

5 The mutation types are listed in TABLE 5. The direction of mutation is clearly nonrandom. For example, A changes more often to G than to either T or C. All transitions, and in particular T-C and A-G, occur more often than transversion. Some nucleotides are more mutable than others. One G→C, one C→G and one C→A transversions were found within the 10 sequenced clones.

10 These mutations were generated very rarely during the error-prone PCR mutagenesis of subtilisin (37). Random-priming process may allow access to a greater range of amino acid substitutions than PCR-based point mutagenesis.

15 It is interesting to note that a short stretch of 5' C GGT ACG CAT GTA GCC GGT ACG 3' (SEQ. ID. NO: 16) at the position 646-667 in parents R1 and R2 was mutated to 5' C GGT ACG ATT GCC GCC GGT ACG 3' (SEQ. ID. NO: 17) in random clone C#6. Since the stretch contains two short repeats at the both ends, the newly introduced mutations may result from a slipped-strand mispairing process instead of point-mutation only process. Since there is no frame-shift, this kind of slippage may be useful for domain conversion.

3. Comparison of different DNA polymerase fidelity in the random-priming process.

During random-priming recombination, homologous DNA sequences are nearly randomly recombined and new point mutations are also introduced. Though these point mutations may provide useful diversity for some *in vitro* evolution applications, they are problematic recombination of beneficial mutations already identified previously, especially when the mutation rate is this high. Controlling error rate during random priming process is particularly important for successfully applying this technique to solve *in vitro* evolution problems. By choosing different DNA polymerase and modifying the reaction conditions, the random priming molecular breeding technique can be adjusted to generate mutant libraries with different error rates.

The Klenow fragment of *E.coli* DNA polymerase I, bacteriophage T4 DNA polymerase, T7 sequenase version 2.0 DNA polymerase, the Stoffel fragment of *Taq* polymerase and *Pfu* polymerase have been tested for the nascent DNA fragment synthesis. The activity profiles of the resulting five populations [see Step (5)] are shown in FIG. 13. To generate these profiles, activities of the individual clones measured in the 96-well plate screening assay are plotted in descending order. The Library/Stoffel and Library/Klenow contain higher percentage of wild-type or inactive subtilisin E clones than that of the Library/*Pfu*. In all five populations, percentage of the wild-type and inactive clones ranges from 17-30%.

EXAMPLE 7

Use of defined flanking primers and staggered extension to recombine single stranded DNA

This example demonstrates the use of the defined primer recombination with staggered extension in the recombination of single stranded DNA.

Method Description

Single-stranded DNA can be prepared by a variety of methods, most easily from plasmids using helper phage. Many vectors in current use are derived from filamentous phages, such as M13mp derivatives. After transformation into cells, these vectors can give rise both to new double-stranded circles and to single-stranded circles derived from one of the two strands of the vector. Single-stranded circles are packaged into phage particles, secreted from cells and can be easily purified from the culture supernatant.

Two defined primers (for example, hybridizing to 5' and 3' ends of the templates) are used here to recombine single stranded genes. Only one of the primers is needed before the final PCR amplification. Extended recombination primers are first generated by the staggered extension process (StEP), which consists of repeating cycles of denaturation followed by extremely abbreviated annealing/extension step(s). The extended fragments are then reassembled into full-length genes by thermocycling-assisted homologous gene assembly in the presence of a DNA polymerase, followed by a gene amplification step.

The progress of the staggered extension process is monitored by removing aliquots (10 ul) from the reaction tube (100 ul starting volume) at various time points in the primer extension and separating DNA fragments by agarose gel electrophoresis. Evidence of effective primer extension is seen as appearance of a low molecular weight 'smear' early in the process which increases in molecular weight with increasing cycle number. Initial reaction conditions are set to allow template denaturation (for example, 94°C-30 second denaturation) followed by very brief annealing/extension step(s) (e.g. 55°C-1 to 15 seconds) repeated through 5-20 cycle increments prior to reaction sampling. Typically, 20-200 cycles of staggered extension are required to generate single stranded DNA 'smears' corresponding to sizes greater than the length of the complete gene.

The experimental design is as in Example 1. Two thermostable subtilisin E mutants R1 and R2 gene are subcloned into vector M13mp18 by restriction digestion with EcoRI and BamHI. Single stranded DNA is prepared as described (39).

Two flanking primer based recombination

Two defined primers, P5N (5'-CCGAG CGTTG CATAT GTGGA AG-3' (SEQ. ID. NO: 18), underlined sequence is NdeI restriction site) and P3B (5'-CGACT CTAGA GGATC CGATT C-3' (SEQ. ID. NO: 19), underlined sequence is BamHI restriction site), corresponding to 5' and 3' flanking primers, respectively, are used for recombination. Conditions (100 ul final volume): 0.15 pmol single-stranded DNA containing R1 and R2 gene (mixed at 1:1) are used as template, 15 pmol of one flanking primer (either P5N or P3B), 1x *Taq* buffer, 0.2 mM of each dNTP, 1.5 mM MgCl₂ and 0.25 U *Taq* polymerase. Program: 5 minutes of 95°C, 80-200 cycles of 30 seconds at 94°C, 5 seconds at 55°C. The single-stranded DNA products of correct size (approximately 1kb) are cut from 0.8% agarose gel after electrophoresis and purified using

QIAEX II gel extraction kit. This purified product is amplified by a conventional PCR. Condition (100 ul final volume): 1-10 ng of template, 30 pmol of each flanking primer, 1x *Taq* buffer, 0.2 mM of each dNTP, 1.5 mM MgCl₂ and 0.25 U *Taq* polymerase. Program: 5 minutes at 95°C, 20 cycles of 30 seconds at 94°C, 30 seconds at 55°C, 1 minute at 72°C. The PCR product is purified, digested with *Nde*I and *Bam*HI and subcloned into pBE3 shuttle vector. This gene library is amplified in *E. coli* HB101 and transferred into *B. subtilis* DB428 competent cells for expression and screening, as described elsewhere (35). Thermostability of enzyme variants is determined in the 96-well plate format described previously (33).

This protocol results in the generation of novel sequences containing novel combinations of mutations from the parental sequences as well as novel point mutations. Screening allows the identification of enzyme variants that are more thermostable than the parent enzymes, as in Example 1.

As is apparent from the above examples, primer-based recombination may be used to explore the vast space of potentially useful catalysts for their optimal performance in a wide range of applications as well as to develop or evolve new enzymes for basic structure-function studies.

While the present specification describes using DNA-dependent DNA polymerase and single-stranded DNA as templates, alternative protocols are also feasible for using single-stranded RNA as a template. By using specific protein mRNA as the template and RNA-dependent DNA polymerase (reverse transcriptase) as the catalyst, the methods described herein may be modified to introduce mutations and crossovers into cDNA clones and to create molecular diversity directly from the mRNA level to achieve the goal of optimizing protein functions. This would greatly simplify the ETS (expression-tagged strategy) for novel catalyst discovery.

In addition to the above, the present invention is also useful to probe proteins from obligate intracellular pathogens or other systems where cells of interest cannot be propagated (38).

Having thus described exemplary embodiments of the present invention, it should be noted by those skilled in the art that the within disclosures are exemplary only and that various other alternatives, adaptations, and modifications may be made within the scope of the present invention.

Accordingly, the present invention is not limited to the specific embodiments as illustrated herein, but is only limited by the following claims.

BIBLIOGRAPHY

1. Shao, Z. and Arnold F. H. 1996. Engineering new functions and altering existing functions. *Curr. Opin. Struct. Biol.* 6: 513-518.
2. Holland, J. H. 1975. *Adaption in natural and artificial systems*. The University Press, Ann Arbor.
3. Goldberg, D. E. 1989. *Genetic algorithms in search, optimization and machine learning*. Addison-Wesley. Reading.
4. Eigen, M. 1971. Self-organization of matter and the evolution of biological macromolecules. *Naturwissenschaften* 58: 465-523.
5. Rechenberg, I. 1973. *Evolutionssstrategie: Optimierung technischer Systeme nach Prinzipien der biologischen Evolution*. Frommann-Holzboog, Stuttgart.
6. Brady, R. M. 1985. Optimization strategies gleaned from biological evolution. *Nature* 317: 804-806.
7. Muhlenbein, H. 1991. The parallel genetic algorithm as function optimizer. *Parallel Computing* 17:619-632.
8. Pál, K. F. 1993. Genetic algorithms for the traveling salesman problem-based on a heuristic crossover operation. *Bio. Cybern.* 69: 539-546.
9. Pál, K. F. 1995. Genetic algorithm with local optimization. *Bio.Cybern.* 73, 335-341.
10. Joyce, G. F. 1992. Directed molecular evolution. *Scientific American*, 267:90-97.
11. Arnold, F. H. 1996. Directed evolution - creating biocatalysts for the future. *Chem. Eng. Sci.* 51:5091-5102.
12. Abelson JN, Ed. 1996. *Combinatorial chemistry. Methods in Enzymology*, 267. Academic Press, Inc., San Diego.
13. Warren MS, Benkovic SJ. 1997. Combinatorial manipulation of three key active site residues in glycineamide ribonucleotide transformylase. *Protein Engineering* 10:63-68.
14. Wang C-I, Yang Q, Craik CS. 1996. Phage display of proteases and macromolecular inhibitors. *Methods in Enzymology* 267:52-68.
15. Moore, J. C. and Arnold, F. H. 1996. Directed evolution of a para-nitrobenzyl esterase for aqueous-organic solvents. *Nature Biotech.* 14: 458-467.
16. Reidhaar-Olson, J. F. and Sauer, R. T. 1988. Combinatorial cassette mutagenesis as a probe of the informational content of protein sequences. *Science* 241: 53-57.
17. Stemmer, W. P. C. 1994a. Rapid evolution of a protein in vitro by DNA shuffling. *Nature*, 370: 389-391.

SUBSTITUTE SHEET (RULE 26)

18. Stemmer, W. P. C. 1994b. DNA shuffling by random fragmentation and reassembly - *in vitro* recombination for molecular evolution. Proc. Natl. Acad. Sci., USA, 91:10747-10751.
19. U.S. Patent No. 5,605,793.
20. Moore, J. C., H.-M. Jin, O. Kuchner and F. H. Arnold. 1997. Strategies for the *in vitro* Evolution of Protein Function: Enzyme Evolution by Random combination of Improved Sequences, J. Molecular Biology, in press.
21. Klenow, H. and I. Henningsen. 1970. Selective elimination of the exonuclease activity of the deoxyribonucleic acid polymerase from *Escherichia coli* B by limited proteolysis. Proc. Natl. Acad. Sci. 65:168
22. Feinberg, A. P. and Vogelstein, B. 1983. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132: 6-13.
23. Nossal, N.G. 1974. DNA synthesis on a double-stranded DNA template by the T4 bacteriophage DNA polymerase and the T4 gene 32 DNA unwinding protein. J. Biol. Chem. 249: 5668-5676.
24. Ehrlich, H.A., PCR Technology, Stockton Press (1989).
25. Oliphant, A. R., Nussbaum, A. L., and Struhl, K. 1986. Cloning of random-sequence oligodeoxynucleotides. Gene 44: 177-183.
26. Hermes, J. D., Blacklow, S. C., and Knowles, J. R. 1990. Searching sequence space by definably random mutagenesis - improving the catalytic potency of an enzyme. Proc. Natl. Acad. Sci. USA 87: 696-700.
27. Leung, D. W., Chen, E., and Goeddel, D. V. 1989. A method for random mutagenesis of a defined DNA segment using a modified polymerase chain reaction. BioTechnique 1: 11-15.
28. Chen, K. and Arnold, F. H. 1993. Tuning the activity of an enzyme for unusual environments: sequential random mutagenesis of subtilisin E for catalysis in dimethylformamide. Proc. Natl. Acad. Sci. USA 90:5681-5622.
29. Sambrook, J., Fritsch, E. F. and Maniatis, T. 1989. Molecular cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
30. Hodgson, C. P. and Fisk R.Z. 1987. Hybridization probe size control: optimized 'oligolabeling'. Nucleic Acids Res. 15:6296.
31. Tabor, S. and Richardson, C. C. 1987. DNA sequence analysis with a modified bacteriophage T7 DNA polymerase. Proc. Natl. Acad. Sci., USA, 84:4767-4771.
32. Tabor, S. and Richardson, C. C. 1989. Selective inactivation of the exonuclease activity of bacteriophage-T7 DNA polymerase by *in vitro* mutagenesis. J.Biol.Chem. 264:6447-6458.

SUBSTITUTE SHEET (RULE 26)

33. Zhao, H. and Arnold, F.H. 1997. Functional and non-functional mutations distinguished by random recombination of homologous genes. *Proc. Natl. Acad. Sci. USA* 94:7997-8000.
34. Zock, J., Cantwell, C., Swartling, J., Hodges, R., Pohl, T., Sutton, K., Rosteck Jr., P., McGilvray, D. & Queener, S. 1994. The *Bacillus subtilis* pnbA gene encoding p-nitrobenzyl esterase - cloning, sequence and high-level expression in *Escherichia coli*. *Gene*, 151, 37-43.
35. Zhao, H. and Arnold, F.H. 1997. Optimization of DNA shuffling for high fidelity recombination. *Nucleic Acids Research*, 25:1307-1308.
36. Lehman, I. R. and Richardson, C. C. 1964. The deoxyribonucleases of *Escherichia coli*. IV. An exonuclease activity present in purified preparations of deoxyribonucleic acid polymerase. *J. Biol. Chem.* 239:233.
37. Shafikhani, S., Siegel, R. A., Ferrari, E. & Schellenberger, V. 1997. Generation of large libraries of random mutants in *Bacillus subtilis* by PCR-based plasmid multimerization. *Biotechniques*, in press.
38. Ebel, T., Middleton, J. F. S., Frisch, A., and Lipp, J. 1997. Characterization of a secretory type *Theileria parva* glutaredoxin homologue identified by novel screening procedure. *J. Biol. Chem.* 272 (5): 3042-3048.
39. Messing, J. 1983. *Methods Enzymology* 101:20-78.
40. Innis, M. A. et al., 1988. *Proc. Natl. Acad. Sci.* 85:9436-9440.

SUBSTITUTE SHEET (RULE 26)

SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- (i) APPLICANTS: Frances H. Arnold
Zhixin Shao
Joseph A. Affholter
Huimin Zhao
Lorraine J. Giver
 - (ii) TITLE OF INVENTION: Recombination of Polynucleotide Sequences Using Defined or Random Primer Sequences
 - (iii) NUMBER OF SEQUENCES: 36
 - (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Oppenheimer Wolff & Donnelly LLP
 - (B) STREET: 2029 Century Park East, Suite 3800
 - (C) CITY: Los Angeles
 - (D) STATE: CA
 - (E) COUNTRY: USA
 - (F) ZIP: 90067
 - (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: Windows
 - (D) SOFTWARE: Microsoft Word 6.0
 - (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
 - (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 60/041,666
 - (B) FILING DATE: March 25, 1997
 - (C) APPLICATION NUMBER: 60/045,211
 - (D) FILING DATE: April 30, 1997
 - (E) APPLICATION NUMBER: 60/046,256
 - (F) FILING DATE: May 12, 1997
 - (G) APPLICATION NUMBER: 08/905,359
 - (H) FILING DATE: August 4, 1997
 - (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Oldenkamp, David J.
 - (B) REGISTRATION NUMBER: 29,421
 - (C) REFERENCE/DOCKET NUMBER: 330187-89
 - (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (310) 788-5000
 - (B) TELEFAX: (310) 277-1297
- (2) INFORMATION FOR SEQ ID NO: 1:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 nucleotides
 - (B) TYPE: nucleotide

SUBSTITUTE SHEET (RULE 26)

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CCG AGC GTT GCA TAT GTG GAA G

22

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 nucleotides

(B) TYPE: nucleotide

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CGA CTC TAG AGG ATC CGA TTC

21

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 nucleotides

(B) TYPE: nucleotide

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GAG CAC ATC AGA TCT ATT AAC

21

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 nucleotides

(B) TYPE: nucleotide

(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GGA GTG GCT CAC AGT CGG TGG

21

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 nucleotides

(B) TYPE: nucleotide

(C) TOPOLOGY: linear

SUBSTITUTE SHEET (RULE 26)

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TTG AAC TAT CGG CTG GGG CGG

21

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 nucleotides
(B) TYPE: nucleotide
(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

TTA CTA GGG AAG CCG CTG GCA

21

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 nucleotides
(B) TYPE: nucleotide
(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

TCA GAG ATT ACG ATC GAA AAC

21

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 nucleotides
(B) TYPE: nucleotide
(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GGA TTG TAT CGT GTG AGA AAG

21

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 nucleotides
(B) TYPE: nucleotide
(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

SUBSTITUTE SHEET (RULE 26)

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
AAT GCC GGA AGC AGC CCC TTC 21
- (2) INFORMATION FOR SEQ ID NO: 10:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 nucleotides
(B) TYPE: nucleotide
(C) TOPOLOGY: linear
- (ii) MOLECULE TYPE: oligonucleotide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
CAC GAC AGG AAG ATT TTG ACT 21
- (2) INFORMATION FOR SEQ ID NO: 11:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 nucleotides
(B) TYPE: nucleotide
(C) TOPOLOGY: linear
- (ii) MOLECULE TYPE: oligonucleotide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
ACT TAA TCT AGA GGG TAT TA 20
- (2) INFORMATION FOR SEQ ID NO: 12:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 nucleotides
(B) TYPE: nucleotide
(C) TOPOLOGY: linear
- (ii) MOLECULE TYPE: oligonucleotide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
AGC CTC GCG GGA TCC CCG GG 20
- (2) INFORMATION FOR SEQ ID NO: 13:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 nucleotides
(B) TYPE: nucleotide
(C) TOPOLOGY: linear
- (ii) MOLECULE TYPE: oligonucleotide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
GGT AGA GCG AGT CTC GAG GGG GAG ATG C 28

SUBSTITUTE SHEET (RULE 26)

(2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 nucleotides
 - (B) TYPE: nucleotide
 - (C) TOPOLOGY: linear

- (ii) MOLECULE TYPE: oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

AGC CGG CGT GAC GTG GGT CAG C

22

(2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 nucleotides
 - (B) TYPE: nucleotide
 - (C) TOPOLOGY: linear

- (ii) MOLECULE TYPE: oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

CCG AGC GTT GCA TAT GTG GAA G

22

(2) INFORMATION FOR SEQ ID NO: 16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 nucleotides
 - (B) TYPE: nucleotide
 - (C) TOPOLOGY: linear

- (ii) MOLECULE TYPE: oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

CGA CTC TAG AGG ATC CGA TTC

21

(2) INFORMATION FOR SEQ ID NO: 17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 nucleotides
 - (B) TYPE: nucleotide
 - (C) TOPOLOGY: linear

- (ii) MOLECULE TYPE: oligonucleotide

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

CGG TAC GCA TGT AGC CGG TAC G

22

SUBSTITUTE SHEET (RULE 26)

(2) INFORMATION FOR SEQ ID NO: 18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 nucleotides
 - (B) TYPE: nucleotide
 - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

CCG TAC GAT TGC CGC CGG TAC G

22

(2) INFORMATION FOR SEQ ID NO: 19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 nucleotides
 - (B) TYPE: nucleotide
 - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

CCG AGC GTT GCA TAT GTG GAA G

22

(2) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 nucleotides
 - (B) TYPE: nucleotide
 - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

CGA CTC TAG AGG ATC CGA TTC

21

(2) INFORMATION FOR SEQ ID NO: 21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 nucleotides
 - (B) TYPE: nucleotide
 - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

GGC GGA GCT AGC TTC GTA

18

(2) INFORMATION FOR SEQ ID NO: 22:

SUBSTITUTE SHEET (RULE 26)

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 nucleotides
 - (B) TYPE: nucleotide
 - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

GAT GTG ATG GCT CCT GGC

18

(2) INFORMATION FOR SEQ ID NO: 23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 nucleotides
 - (B) TYPE: nucleotide
 - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

CAG AAC ACC GAT TGA GTT

18

(2) INFORMATION FOR SEQ ID NO: 24:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 nucleotides
 - (B) TYPE: nucleotide
 - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: oligonucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

AGT GCT TTC TAA ACG ATC

18

(2) INFORMATION FOR SEQ ID NO: 25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH 4 amino acids
 - (B) TYPE: peptide
 - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

Ala Ala Pro Phe

(2) INFORMATION FOR SEQ ID NO: 26:

- (i) SEQUENCE CHARACTERISTICS:

SUBSTITUTE SHEET (RULE 26)

(A) LENGTH: 4050 nucleotides
 (B) TYPE: nucleotide
 (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: polynucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

GGGATCCTCT AAAGTCGACC TGCAGCGTGC CCAGCTGTTC GTGGTGGTGA TCGCGGCCGC	60
GCTGGCCGCC GTCGCGGTGC CCGCCGCCGG GCCGATCGAG TTCGTCGCCT TCGTCGTGCC	120
GCAGATCGCC CTGCGGCTCT GCGGCGGCAG CCGGCCGCC CTGCTCGCCT CGGCGATGCT	180
CGGCGCGCTG CTGGTGGTCG GCGCCGACCT GGTGCTCAG ATCGTGGTGG CGCGAAGGA	240
GCTGCCGGTC GGCCTGCTCA CCGCGATGAT CGGCACCCG TACCTGCTCT GGCTCCTGCT	300
TCCGCGATCA AGAAAGGTGA GCGATGAAC GCCCGCCTGC GTGGCGAGGG CCTGCACCTC	360
GCGTACGGGG ACCTGACCGT GATCGACGGC CTCGACGTCG ACGTGACGA CGGGCTGGTC	420
ACCACCATCA TCGGSCCAA CCGGTGCGGC AAGTCGACGC TGCTCAAGGC GCTCGGCCGG	480
CTGCTGCGCC CGACCGCGG GCAGGTGCTG CTGGACGGCC GCCGCATCGA CCGGACCCCC	540
ACCCGTGACG TGCCCCGGGT GTCGCGGTG CTGCCGAGT CGCCACCGC GCCGAAGGG	600
CTCACCGTCG CCGACCTGGT GATCGCGGGC CGGCACCCGC ACCAGACCTG GTTCCGGCAG	660
TGGTCGCGCG ACGACGAGGA CCAGGTGCGC GACGCGCTGC GCTGGACCGA CATGCTGGCG	720
TACGCGGACC GCCCGGTGGA CGCCCTCTCC GCGGTGAGC GCCAGCGCGC CTGGATCAGC	780
ATGGCGCTGG CCCAGGGCAC CGACCTGCTG CTGCTGGACG AGCCGACCAC CTTCTCGAC	840
CTGGCCCAAC AGATCGACGT GCTGGACCTG GTCGCGCGC TGCACGCCGA GATGGGCCGG	900
ACCGTGGTGA TGGTGCTGCA CGACCTGAGC CTGGCCGCC GGTACGCCGA CCGGCTGATC	960
GCGATGAAGG ACGGCCGGAT CGTGGCGAGC GGGGCGCCGG ACGAGGTGCT CACCCCGCG	1020
CTGCTGGAGT CGGTCTTCGG GCTGCGCGCG ATGGTGGTGC CCGACCCGGC GACCGGCACC	1080
CCGCTGGTGA TCCCCCTGCC GCGCACCGCC ACCTCGGTGC GGGCCTGAAA TCGATGAGCG	1140
TGGTGTCTTC ATCGGCCTGC CGAGCGATGA GAGTATGTGG GCGGTAGAGC GAGTCCCGAG	1200
GGGGAGATGC CGCGTGACG TCCTCGTACA TCGCCTGAA AGCAGCAGCG ATCGCCTTCG	1260
GTGTGATCGT GCGACCGCA ACCGTGCCGT CACCCGCTTC CGGACGGGAA CATGACGGCG	1320
GCTATGCGGC CCTGATCCGC CGGGCCTCGT ACGGCGTCCC GCACATCACC GCCGACGACT	1380
TCCGGAGCCT CGGTTCGGC GTCGGGTACG TGCAGGCCGA GGACAACATC TCGCTCATCG	1440
CCGAGAGCGT GGTGACGGCC AACGGTGAGC GGTGCGGTG GTTCGGTGCG ACCGGGCCGG	1500

SUBSTITUTE SHEET (RULE 26)

ACGACGCCGA TGTGCGCAGC GACCTCTTCC ACCGCAAGGC GATCGACGAC CGCGTCGCCG 1560
AGCGGCTCCT CGAAGGGCCC CGCGACGGCG TGCGGGCGCC GTCGGACGAC GTCCGGGACC 1620
AGATGCGCGG CTTGCTCGCC GGCTACAACC ACTTCCTACG CCGCACCAGC GTGCACCGCC 1680
TGACCGACCC GCGGTGCGCG GCGAAGGCCT GGGTGGCGCC GCTCTCCGAG ATCGATCTCT 1740
GGCGTACATT GTGGGACAGC ATGGTCCGGG CCGGTTCCGG GCGCTGCTC GACGGCATCG 1800
TCGCGCGGAC GCCACCGACA GCCGCCGGGC CCGGTCAGC CCGGAGGCA CCGACGCCG 1860
CCGCGATCGC CGCCGCCCTC GACGGGACGA GCGCGGCAT CCGCAGCAAC GCGTACGGCC 1920
TCGGCGCGCA GGCCACCGTG AACGGCAGCG GGATGGTGCT GGCCAACCG CACTTCCGT 1980
GGCAGGGCGC CGCACGCTTC TACCGGATGC ACCTCAAGGT GCCCGGCCGC TACGACGTGC 2040
AGGGCGCGGC GCTGGTCGGC GACCGATCA TCGAGATCGG GCACAACGC ACGGTGCGCT 2100
GGAGCCACAC CGTCTCCACC GCCCGCGGT TCGTGTGGCA CCGCTGAGC CTGTCGCCG 2160
GCGACCCAC CTCTATTAC GTCGACGCC GGCCGAGCG GATGCGGCC CGCACGGTCA 2220
CGGTCCAGAC CGGCAGCGC CCGTCAGCC GCACCTTCCA CGACACCGC TACGGCCCG 2280
TGGCCGTGGT GCCGGGCACC TTCGACTGA GCGCGCCAC CGGTACGCC ATCACCGAG 2340
TCAACGCGGG CAACAACCGC GCCTTCGACG GGTGGTGGG GATGGGCCAG GCCAAGGAG 2400
TCCGGGCGCT CAAGGCGGTC CTCGACCGC ACCAGTTCCT GCCCTGGGT AACGTGATCG 2460
CCGCCGACGC GCGGGCGAG GCCCTCTACG GCGATCATT GGTGCTCCC CGGGTGACCG 2520
GCGCGCTGCG TGCCGCTGCG ATCCGCGCG CGTTCAGCC GCTCTACGCC TCCAGCGGCC 2580
AGGCGGTCTT GAGCGTTCC CGGTGGAAT GCGCGCTCG CGCCGACCC GACCGCGCG 2640
TCCGGGCGAT TCTCGGCCG GCGAGCCTGC CGGTGCGGT CCGCGACGAC TACGTACCA 2700
ACTCCAACGA CAGTCACTGG CTGGCCAGCC CGGCCGCCG GCTGGAAGGC TTCCCGCGGA 2760
TCCTCGGCAA CGAACGCACC CCGCGAGCC TGGCACCCG GCTCGGGCTG GACCAGATCC 2820
AGCAGCGCCT CGCCGCGAG GACGCTGTC CCGGCAAGG CTTACACCAC GCCCGGCTCT 2880
GGCAGGTCAT GTTCGGCAAC CGGATGCAG GCGCGAAGT CGTCCGCGAC GACCTGCTCG 2940
CGCTCTGCG CGCCAGCCG ACCGCGAGC CCTCGAACG CGCGATCGTC GACCTCACC 3000
CGGCTGCGC GCGCTGTTC CGCTTCGATG AGCGTGCCGA CCTGGACAGC CGGGGCGCG 3060
ACCTGTTTAC CGAGTTCGCC CTCGCGGGCG GAATCAGGT CCGCGACACC TTCGAGGTGA 3120
CGGATCCGGT ACGCACCCCG CGCCGTCTGA ACACCACGGA TCCGCGGTA CGGACGGCG 3180
TCGCGACGC CGTGCAACCG CTCGCGGCA TCCCCCTCGA CGCGAAGCTG GGAGACATTC 3240

SUBSTITUTE SHEET (RULE 26)

- 57 -

ACACCGACAG CCGCGGGGAA CGGCGCATCC CCATCCACGG TGGCCCGGGG GAAGCAGGCA 3300
 CCTTCAACGT GATCACC AAC CCGCTCGTGC CGGGCGTGGG ATACCCGCAG GTCGTCCACG 3360
 GAACATCGTT CGTGATGGCC GTCGAATCG GCCCGCACGG CCCGTCCGGA CGGCAGATCC 3420
 TCACCTATGC GCAGTCGACG AACCCGAACT CACCCTGGTA CGCCGACCAG ACCGTGCTCT 3480
 ACTCGCGGAA GGGCTGGGAC ACCATCAAGT ACACCGAGGC GCAGATCGCG GCCGACCCGA 3540
 ACCTGCGCGT CTACCGGGTG GCACAGCGGG GACGCTGACC CACGTACCGC CGGCTCGGCC 3600
 CGTGCGGGGG CGCAGGGCGC CGATCGTCTC TGCATCGCCG GTCAGCCGGG GCCTGCGTCG 3660
 ACCGGCGGGG GCCGGTCGAC GCCCGCGTCC CGGCGCAGCG ACTGGCTGAA GCGCCAGGCG 3720
 TCGGCGGCCC GGGGCAGGTT GTTGAACATC ACGTACGCCG GGCCGCGGTC GAGGATGCCG 3780
 GCGAGGTGTG CCAGCTCGGC ATCCGTGTAC ACATGCGGGG CGCCGGTGAT GCCGTGCAGC 3840
 CGGTAATAGG CCATCGGCGT CAGACTGCGG CGCAGGAACG GGTCCGGCGC GTGGGTGAGG 3900
 TCCAGTCTCT GGCACAAGCC CTCGACCACC TCGTCCGGCC ACGGGCCGCG CGGCTCCCAC 3960
 AACAGCCGGA CACCGGCCGG CCGGCGCGCT CGGGCGCAGA ACTCACGCAG TCGCGCGATG 4020
 GCGGGTTCGG TCGGCCGGA ACTCGCGGG 4050

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4101 nucleotides
- (B) TYPE: nucleotide
- (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: polynucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

AAGCTTGCAT GCCTGCAGCG TGCCAGCTG TTCGTGGTGG TGATCGCGGC CGCGCTGGCC 60
 GCCGTGCGGG TCGCCGCGGC CGGGCCGATC GAGTTCGTG CCTTCGTGCT GCCGCAGATC 120
 GCCCTGCGGC TCTGCGGCGG CAGCCGGCCG CCCCTGCTCG CCTCGGCGAT GCTCGGCGCG 180
 CTGCTGGTGG TCGGCGCGGA CCTGGTCTGT CAGATCGTGG TGGCGCCGAA GGAGCTGCCG 240
 GTCGGCCTGC TCACCGCGAT GATCGGCACC CCGTACCTGC TCTGGCTCCT GCTTCGGCGA 300
 TCAAGAAAGG TGAGCGGATG AACGCCCGCC TCGTGGCGA GGGCCTGCAC CTGCGTACG 360
 GGGACCTGAC CGTGATCGAC GGCTTCGACG TCGACGTGCA CGACGGGCTG GTCACCACCA 420
 TCATCGGGCC CAACGGGTGC GGCAAGTCGA CGCTGCTCAA GCGCTCGGC CGGCTGCTGC 480
 GCGCGACCGG CGGGCAGGTG CTGCTGGACG GCCCGCGCAT CGACCGGACC CCCACCGTGC 540

SUBSTITUTE SHEET (RULE 26)

ACGTGGCCCC GGTGCTCGGC GTGCTGCCGC AGTCGCCAC CGCGCCCGAA GGGCTCACC 600
TCGCCGACCT GGTGATGCGC GGCCGGCACC CGCACCAGAC CTGGTTCCGG CAGTGGTCGC 660
GCGACGACGA GGACCAGGTC GCCGACGCGC TCGCTGGAC CGACATGCTG GCGTACGCGG 720
ACCGCCCGGT GGACGCCCTC TCCGGCGGTC AGCGCCAGCG CGCCTGGATC AGCATGGCGC 780
TGGCCCAGGG CACCGACCTG CTGCTGCTGG ACGAGCCGAC CACCTTCCTC GACTGGCCC 840
ACCAGATCGA CGTGTGCGC CTGCTCCGCC GGCTGCACGC CGAGATGGGC CGGACCGTGG 900
TGATGGTGCT GCACGACCTG AGCCTGGCCG CCCGGTACGC CGACCGGCTG ATCGCGATGA 960
AGGACGGCCG GATCGTGGCG AGCGGGGCGC CGGACGAGGT GCTCACCCTG GCGCTGCTGT 1020
AGTCGGTCTT CGGGCTGCGC GCGATGGTGG TGCCCGACCC GCGGACCGGC ACCCGCTGG 1080
TGATCCCCCT GCCGCGCACC GCCACCTCGG TGCGGGCCTG AAATCGATGA GCGTGGTTGC 1140
TTCATCGGCC TGCCGAGCGA TGAGAGTATG TGGGCGGTAG AGCGAGTCTC GAGGGGAGA 1200
TGCCGCGTG ACGTCTCTGT ACATGCGCCT GAAAGCAGCA GCGATCGCCT TCGGTGTGAT 1260
CGTGGCGACC GCAGCCGTGC CGTCACCCGC TTCGGCAGG GAACATGACG GCGGCTATGC 1320
GGCCCTGATC CGCCGGGCTT CGTACGGCGT CCCGCACATC ACCGCCGACG ACTTCGGGAG 1380
CCTCGGTTTC GCGCTCGGCT ACGTGCAGGC CGAGGACAAC ATCTGCTCA TCGCCGAGAG 1440
CGTGGTAACG GCCAACGGTG AGCGGTGCGG GTGGTTCCGT GCGACCGGGC CGGACGACGC 1500
CGATGTGCGC AGCGACCTCT TCCACCGCAA GCGATCGAC GACCGCGTCG CCGAGCGGCT 1560
CCTCGAAGGG CCCCGCGACG GCGTGCGGGC GCCGTGCGAC GACGTCCGGG ACCAGATGCG 1620
CGGCTTCGTC GCCGGCTACA ACCACTTCCT ACGCCGCACC GCGGTGCACC GCCTGACCGA 1680
CCCGGCGTGC CGCGGCAAGG CCTGGGTGCG CCCGCTCTCC GAGATCGATC TCTGGCGTAC 1740
GTGCTGGGAC AGCATGGTCC GGGCCGCTT CCGGGCGCTG CTCGACGGCA TCGTCGCCGC 1800
GACGCCACCT ACAGCCCGCG GGGCCGCTC AGCCCCGAG GCACCGGACG CGCCCGGAT 1860
CGCCGCCGCC CTCGACGGGA CGAGCGCGGG CATCGGCAGC AACCGGTACG GCCTCGGCGC 1920
GCAGGCCACC GTGAACGGCA GCGGGATGGT GCTGGCCAAC CCGCACTTCC CGTGGCAGGG 1980
CGCCGAACGC TTCTACCGGA TGCACCTCAA GGTGCCCGGC CGCTACGACG TCGAGGGCGC 2040
GGCGCTGATC GCGACCCGA TCATCGGGAT CGGGCACAAC CGCAGGTGCT CCGGAGCCA 2100
CACCGTCTCC ACCGCCCGCC GGTTCGTGTG GCACCGCCTG AGCCTCGTGC CCGGCGACCC 2160
CACCTCCTAT TACGTGACG GCCGGCCCGA GCGATGCGC GCCCGCACGG TCACGGTCCA 2220
GACCGGCAGC GGCCCGGTCA GCGCACCTT CCACGACACC CGCTACGGCC CGGTGGCGCT 2280

SUBSTITUTE SHEET (RULE 26)

GATGCCGGGC ACCTTCGACT GGACGCCGGC CACCGCGTAC GCCATCACCG ACGTCAACGC 2340
GGGCAACAAC CGCGCCTTCG ACGGGTGGCT GCGGATGGGC CAGGCCAAGG ACGTCCGGGC 2400
GCTCAAGGCG GTCTCGACC GGCACCAATT CCTGCCCTGG GTCAACGTGA TCGCCGCCGA 2460
CGCGCGGGC GAGGCCCTCT ACGGCGATCA TTCGGTCGTC CCCCGGGTGA CCGGCGCGCT 2520
CGCTGCCGCC TGCATCCCGG CGCGTTCCA GCCGCTCTAC GCCTCCAGCG GCCAGGCGGT 2580
CCTGGACGGT TCCCGGTCGG ACTGCGCGCT CGGCGCCGAC CCCGACGCCG CGGTCCCGGG 2640
CATTCTCGGC CCGGCGAGCC TGCCGGTGGG GTTCCGCGAC GACTACGTCA CCAACTCCAA 2700
CGACAGTCAC TGGCTGGCCA GCCCGGCCGC CCCGCTGGAA GGCTTCCCGC GATCCTCGG 2760
CAACGAACGC ACCCCGCGCA GCCTGCGCAC CCGGCTCGGG CTGGACCAGA TCCAGCAGCG 2820
CCTCGCCGGC ACGGACGGTC TGCCCGGCAA GGGCTTCACC ACCGCCCGGC TCTGGCAGGT 2880
CATGTTGGC AACCGGATGC ACGGCGCGGA ACTCGCCCGC GACGACCTGG TCGCGCTCTG 2940
CCGCCGCCAG CCGACCGCGA CCGCCTCGAA CGGCGCGATC GTCGACCTCA CCGCGGCCTG 3000
CAOCCGCGTG TCCCGCTTCG ATGAGCGTGC CGACCTGGAC AGCCGGGGCG CGCACCTGTT 3060
CACCGAGTTC GCCCTCGCGG GCGGAATCAG GTTCGCGAC ACCTTCGAGG TGACCGATCC 3120
GGTACGCACC CCGCGCCGTC TGAACACCAC GGATCCCGGG GTACGGACCG CGCTCGCCGA 3180
CGCCGTGCAA CGGCTCGCCG GCATCCCCCT CGACGCGAAG CTGGGAGACA TCCACACCGA 3240
CAGCCGCGGC GAACGGCGCA TCCCATCCA CGGTGGCCGC GGGGAAGCAG GCACCTTCAA 3300
CGTGATCACC AACCCGCTCG TGCCGGGCGT GGGATACCCG CAGGTCGTCC ACGGAACATC 3360
GTTGCTGATG GCCGTGGAAC TCGGCCCGCA CGGCCCGTCG GGACGGCAGA TCCTCACCTA 3420
TGCGCAGTCG ACGAACCAGA ACTCACCTG GTACGCGAC CAGACCGTGC TCTACTCGCG 3480
GAAGGGCTGG GACACCATCA AGTACACCGA GCGCAGATC GCGGCCGACC CGAACCTGGC 3540
CGTCTACCGG GTGGCACAGC GGGGACGCTG ACCCACTCA CGCCGGCTCG GCCCGTGGCG 3600
GGGCGCAGGG CGCGATCGT CTCTGCATCG CCGGTCAGCC GGGGCTGCG TCGACCGGCG 3660
GCGGCCGGTC GACGCCCGCG TCCCGGCGCA GCGACTGGCT GAAGCGCCAG GCGTCGGCGG 3720
CCCGGGGCAG GTTGTGAAC ATCAGGTACG CCGGGCCGCC GTCGAGGATG CCGGCGAGGT 3780
GTGCCAGCTC GGCATCCGTA TACACATGCC GGGCGCCGGT GATGCCGTGC AGCCGGTAAT 3840
AGGCCATCGG CGTCAGACTG CGGCGCAGGA ACGGGTCGGC GCGGTGGGTC AGGTCCAGCT 3900
CCTGGCACA GCCCTCGACC ACCTCGTCCG GCCACGGGCC GCGCGGCTCC CACAACAGCC 3960
GGACACCGGC CGGCCGGCGC GCTCGGGCGC AGAACTCACG CAGTCGCGCG ATGGCGGGTT 4020

SUBSTITUTE SHEET (RULE 26)

CGGTCGGCCG GAAACTCGCC GGGCACTGCA GGTGACTCT AGAGGATCCC CGGGTACCGA 4080
 GCTCGAATTC GTAATCATGT C 4101

(2) INFORMATION FOR SEQ ID NO: 28:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 4093 nucleotides
 (B) TYPE: nucleotide
 (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: polynucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

AAGCTTGCA TGCCTGCAGCG TGCCAGCTG TTCGTGGTGG TGATCGCGGC CGGCTGGCC 60
 GCCGTCGCGG TCGCCGCGGC CGGGCCGATC GAGTTCGTCT CCTTCGTCTGT GCCGAGATC 120
 GCCCTGCGGC TCTGCGGCGG CAGCCGCGCG CCCCTGCTCG CCTCGGCGAT GCTCGGCGCG 180
 CTGCTGGTGG TCGGCGCCGA CCTGGTCTGT CAGATCGTGG TGGCGCCGAA GGAGCTGCCG 240
 GTGCGCTGCT TCACCGCGAT GATCGGCACC CCGTACCTGC TCTGGCTCCT GCTTCGGCGA 300
 TCAAGAAAGG TGAGCGGATG AACGCCCGCC TCGTGGCGA GGGCCTGCAC CTCGCGTACG 360
 GGGACCTGAC CGTGATCGAC GGCCTCGACG TCGACGTGCA CGACGGGCTG GTCACCACCA 420
 TCATCGGGCC CAACGGGTGC GGCAAGTCGA CGCTGCTCAA GCGGCTCGGC CGGCTGCTGC 480
 GCCCGACCGG CGGGCAGGTG CTGCTGGACG GCCGCGCAT CGACCGGACC CCCACCCGTG 540
 ACGTGGCCCG GGTGCTCGGC GTGCTGCCGC AGTCGCCAC CGCGCCGAA GGGCTCACCG 600
 TCGCCGACCT GGTGATGCGC GGCCGGCACC CGCACCAGAC CTGGTTCGGG CAGTGGTCTG 660
 GCGACGACGA GGACCAGGTC GCCGACGCGC TCGCTGGAC CGACATGCTG GCGTACGCGG 720
 ACGCCCGGT GGACGCCCTC TCCGGCGGTC AGCGCCAGCG CGCCTGGATC AGCATGGCGC 780
 TGGCCAGGG CACCGACCTG CTGCTGCTGG ACGAGCCGAC CACCTTCCTC GACCTGGCCC 840
 ACCAGATCGA CGTGCTGGAC CTGGTCCGCC GGCTGCACGC CGAGATGGGC CGGACCGTGG 900
 TGATGGTGCT GCACGACCTG AGCCTGGCCG CCCGGTACGC CGACCGGCTG ATCGCATGA 960
 AGGACGGCCG GATCGTGGCG AGCGGGGCGC CGGACGAGGT GCTCACCCCG GCGCTGCTGG 1020
 AGTCGGTCTT CGGGCTGCGC GCGATGGTGG TGCCCGACCC GCGGACCGGC ACCCGCTGG 1080
 TGATCCCCCT GCCGCGCACC GCCACCTCGG TCGGGGCTG AAATCGATGA GCGTGGTTGC 1140
 TTCATCGGCC TGCCGAGCGA TGAGAGTATG TGGGCGGTAG AGCGAGTCCC GAGGGGAGGA 1200
 TGCCGCGGTG ACGTCTCTGT ACATGCGCCT GAAAGCAGCA GCGATCGCCT TCGGTGTGAT 1260

SUBSTITUTE SHEET (RULE 26)

CGTGGCGACC	GCAACCGTGC	CGTACCCCGC	TTCCGGCAGG	GAACATGACG	GCGGCTATGC	1320
GGCCCTGATC	CGCCGGGCCT	CGTACGGCGT	CCCGCACATC	ACCGCCGACG	ACTTCGGGAG	1380
CCTCGGTTTC	GGCGTCGGGT	ACGTGCAGGC	CGAGGACAAC	ATCTGCGTCA	TCGCCGAGAG	1440
CGTGGTGACG	GCCAACGGTG	AGCGGTCCCG	GTGGTTCCGT	GCGACCGGGC	CGGACGACGC	1500
CGATGTGCGC	AGCGACCTCT	TCCACCGCAA	GGCGATCGAC	GACCGCGTCG	CCGAGCGGCT	1560
CCTCGAAGGG	CCCCCGGACG	GCCTGCGGGC	GCCGTCCGAC	GACGTCCGGG	ACCAGATGCG	1620
CGGCTTCGTC	GCCGGCTACA	ACCACTTCCT	ACGCCGCACC	GGCGTGCACC	GCCTGACCGA	1680
CCCCGGGTGC	CGCGGCAAGG	CCTGGGTGCG	CCCGCTCTCC	GAGATCGATC	TCTGGCGTAC	1740
ATTGTGGGAC	AGCATGGTCC	GGGCCGGTTC	CGGGGCGCTG	CTCGACGGCA	TCGTCCGCGC	1800
GACGCCACCG	ACAGCCCGCG	GGCCCGCGTC	AGCCCGCGAG	GCACCCGACG	CCGCCCGGAT	1860
CGCCGCCGCC	CTCGACGGGA	CGAGCGCGGG	CATCGGCAGC	AACGCGTACG	GCCTCGGCGC	1920
GCAGGCCACC	GTGAACGGCA	GCGGGATGGT	GCTGGCCAAC	CCGCACTTCC	CGTGGCAGGG	1980
CGCCGCACGC	TTCTACCGGA	TGCACCTCAA	GGTGCCCGGC	CGCTACGACG	TCGAGGGCGC	2040
GGCGCTGGTC	GGCGACCGGA	TCATCGAGAT	CGGGCACAAC	CGCACGGTCG	CCTGGAGCCA	2100
CACCGTCTCC	ACCGCCCGCC	GGTTCGTGTG	GCACCGCCTG	AGCCTCGTGC	CGGGCGACCC	2160
CACCTCTAT	TACGTGACG	GCCGGCCCGA	GCGGATGCGC	GCCCGCACGG	TCACGGTCCA	2220
GACCGGCAGC	GGCCCGGTCA	GCCGCACCTT	CCACGACACC	CGCTACGGCC	CGGTGGCCGT	2280
GGTGCCGGGC	ACCTTCGACT	GGACGCCGGC	CACCGCGTAC	GCCATCACCG	ACGTCAACGC	2340
GGGCAACAAC	CGCGCCTTCG	ACGGGTGGCT	GCGGATGGGC	CAGGCCAAGG	ACGTCCGGGC	2400
GCTCAAGGCG	GTCTCGACC	GGCACCAGTT	CCTGCCCTGG	GTCAACGTGA	TCGCCGCCGA	2460
CGCGCGGGGC	GAGGCCCTCT	ACGGCGATCA	TTGCGTCGTC	CCCCGGGTGA	CCGGCGCGCT	2520
CGCTGCCGCC	TGCATCCCGG	CGCGGTTCGA	GCCGCTCTAC	GCCTCCAGCG	GCCAGGCGGT	2580
CCTGGACGGT	TCCCGGTCCG	ACTGCGCGCT	CGGCGCGGAC	CCCGACGCGG	CGGTCCCGGG	2640
CATTCTCGGC	CCGGCGAGCC	TGCCGGTGCG	GTTCCGCGAC	GACTACGTCA	CCAACTCCAA	2700
CGACAGTCAC	TGGCTGGCCA	GCCCGGCCGC	CCCGCTGGAA	GGCTTCCCGC	GGATCCTCGG	2760
CAACGAACGC	ACCCCGCGCA	GCCTGCGCAC	CCGGCTCGGG	CTGGACCAGA	TCCAGCAGCG	2820
CCTCGCCGGC	ACGACCGGTC	TGCCCGGCAA	GGGCTTCACC	ACCGCCCGGC	TCTGGCAGGT	2880
CATGTTCCGC	AACCGGATGC	ACGGCGCGGA	ACTCGTCCGC	GACGACCTGG	TCGGCTCTTG	2940
CCGCCGCCAG	CCGACCGCGA	CCGCCTCGAA	CGGCGCGATC	GTGACCTCA	CCGCCGCCCTG	3000

SUBSTITUTE SHEET (RULE 26)

CACGGCGCTG TCCCGCTTCG ATGAGCGTGC CGACCTGGAC AGCCGGGGCG CGCACCTGTT 3060
CACCGAGTTC GCCCTCGCGG GCGGAATCAG GTTCGCCGAC ACCTTCGAGG TGACCGATCC 3120
GGTACGCACC CCGCGCCGTC TGAACACCAC GGATCCGCGG GTACGGACGG CGCTCGCCGA 3180
CGCCGTGCAA CGGCTCGCCG GCATCCCCCT CGACGCGAAG CTGGGAGACA TTCACACCGA 3240
CAGCCGCGGC GAACGCGCA TCCCCATCCA CGGTGGCCGC GGGAAGCAG GCACCTTCAA 3300
CGTGATCACC AACCCGCTCG TGCCGGCGT GGGATACCG CAGGTCTGCC ACGGAACATC 3360
GTTCGTGATG GCCGTGGAAC TCGGCCGCA CGGCCGCTCG GGACGGCAGA TCCTCACCTA 3420
TGCGCAGTCG ACGAACCCGA ACTCACCTG GTACGCCGAC CAGACCGTGC TCTACTCGCG 3480
GAAGGGCTGG GACACCATCA AGTACACCGA GGCGCAGATC GCGGCCGACC CGAACCTGCG 3540
CGTCTACCGG GTGGCACAGC GGGGACGCTG ACCCAGTCA CGCCGGCTCG GCCCGTGCGG 3600
GGGCGCAGGG CGCGATCGT CTCTGCATCG CCGGTCAGCC GGGGCTGCG TCGACCGGG 3660
GCGGCCGCTC GAOGCCCGCG TCCCGGCGCA GCGACTGGCT GAAGCGCCAG GCGTCGGCGG 3720
CCCGGGGCGG GTTGTGAAC ATCACGTACG CCGGGCCGCC GTCGAGGATG CCGGCGAGGT 3780
GTGCCAGCTC GGCATCCGTG TACACATGCC GGGCGCCGGT GATGCCGTGC AGCCGGTAAT 3840
AGGCCATCGG CGTCAGACTG CGGCGCAGGA ACGGTCGGC GCGTGGGTC AGGTCCAGCT 3900
CCTGGCACAA GCCCTCGACC ACCTCGTCCG GCCACGGGCC GCGCGGCTCC CACAACAGCC 3960
GGACACCGGC CGGCGGCGC GCTCGGGCGC AGAACTCACG CAGTCGCGCG ATGGCGGGTT 4020
CGGTGCGCCG GAAACTCGCC GGGCACTGCA GGTGACTCT AGAGGATCCC CCGGGTACCG 4080
AGCTCGAATT CGT 4093

(2) INFORMATION FOR SEQ ID NO: 29:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3222 nucleotides
(B) TYPE: nucleotide
(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: polynucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

GCCGGCTGCA CGCCGAGATG GGCCGGACCG TGGTGATGGT GCTGCACGAC CTGAGCCTGG 60
CCGCCCCGTA CGCCGACCGG CTGATCGCGA TGAAGGACGG CCGGATCGTG GCGAGCGGGG 120
CGCCGGACGA GGTGCTCACC CCGGCGCTGC TGGAGTCGGT CTTCGGGCTG CGCGCGATGG 180
TGGTGCCCGA CCCGGCGACC GGCACCCCGC TGGTGATCCC CTTGCCGCGC ACCGCCACCT 240

SUBSTITUTE SHEET (RULE 26)

CGGTGCGGGC	CTGAAATCGA	TGAGCGTGGT	TGCTTCATCG	GCCTGCCGAG	CGATGAGAGT	300
ATGTGGGCGG	TAGAGCGAGT	CCCGAGGGGG	AGATGCCGCC	GTGACGTCTT	CGTACATGCG	360
CCTGAAAGCA	GCAGCGATCG	CCTTCGGTGT	GATCGTGGCG	ACCGCAACCG	TGCCGTCACC	420
CGCTTCCGGC	AGGGAACATG	ACGGCGGCTA	TGCGGCCCTG	ATCCGCCCGG	CCTCGTACGG	480
CGTCCCGCAC	ATCACCGCCG	ACGACTTCGG	GAGCCTCGGT	TTCGGCGTCG	GGTACGTGCA	540
GGCCGAGGAC	AACATCTGCG	TCATCGCCGA	GAGCGTGGTG	ACGGCCAACG	GTGAGCGGTC	600
GCGGTGGTTC	GGTGCGACCG	GGCCGGACGA	CGCCGATGTG	CGCAGCGACC	TCTTCCACCG	660
CAAGGCGATC	GACGACCGCG	TGCGCGAGCG	GCTCCTCGAA	GGGCCCGCGG	ACGGCGTGCG	720
GGCGCCGTCG	GACGACGTCC	GGGACCAGAT	GCGCGGCTTC	GTGCGCCGGT	ACAACCACTT	780
CCTACGCCGC	ACCGGCGTGC	ACCGCCTGAC	CGACCCGGCG	TGCCGCGGCA	AGGCCTGGGT	840
GCGCCCGCTC	TCCGAGATCG	ATCTCTGGCG	TACATTGTGG	GACAGCATGG	TCCGGGCCGG	900
TTCCGGGGCG	CTGCTCGACG	GCATCGTCGC	CGCGACGCCA	CCGACAGCCG	CGGGGCCCGC	960
GTCAGCCCCG	GAGGCACCCG	ACGCCGCCGC	GATCGCCGCC	GCCCTCGACG	GGACGAGCGC	1020
GGGCATCGGC	AGCAACGCGT	ACGGCCTCGG	CGCGCAGGCC	ACCGTGAACG	GCAGCGGGAT	1080
GGTGCTGGCC	AACCCGCACT	TCCCGTGGCA	GGGCGCCGCA	CGCTTCTACC	GGATGCACCT	1140
CAAGTGCCCC	GGCCGCTACG	ACGTGAGGGG	CGCGGCGCTG	GTGCGCGACC	CGATCATCGA	1200
GATCGGGCAC	AACCGCACGG	TGCGCTGGAG	CCACACCGTC	TCCACCGCCC	GCCGGTTCGT	1260
GTGGCACC GC	CTGAGCCTCG	TGCCCGGCGA	CCCCACCTCC	TATTACGTGC	ACGGCCGGCC	1320
CGAGCGGATG	CGCGCCCGCA	CGGTACGGT	CCAGACCGGC	AGCGGCCCGG	TCAGCCGCAC	1380
CTTCCACGAC	ACCCGCTACG	GCCCGGTGGC	CGTGATGCCG	GGCACCTTCG	ACTGGACGCC	1440
GGCCACCGCG	TACGCCATCA	CCGACGTCAA	CGCGGGCAAC	AACCGCGCCT	TGACGGGTG	1500
GCTGCGGATG	GGCCAGGCCA	AGGACGTCCG	GGCGCTCAAG	GCGGTCTCTG	ACCGGCACCA	1560
GTTCCTGCCC	TGGGTCAACG	TGATCGCCGC	CGACGCGCGG	GGCGAGGCCC	TCTACGGCGA	1620
TCATTGCGTC	GTCCCCCGGG	TGACCGGCGC	GCTCGCTGCC	GCCTGCATCC	CGGCGCGGTT	1680
CCAGCCGCTC	TACGCTTCCA	GCGGCCAGGC	GGTCCTGGAC	GGTTCCCGGT	CGGACTGCGC	1740
GCTCGGCGCC	GACCCCGACG	CGCGGTCCC	GGCAATTCTC	GGCCCGGCGA	GCCTGCCCGT	1800
GCGGTCCGCG	GACGACTACG	TCACCAACTC	CAACGACAGT	CACTGGCTGG	CCAGCCCGGC	1860
CGCCCCGCTG	GAAGGCTTCC	CGCGGATCCT	CGGCAACGAA	CGCACCCCGC	GCAGCCTGCG	1920
CACCCGGCTC	GGGCTGGACC	AGATCCAGCA	GCGCCTCGCC	GGCACGGACG	GTCTGCCCGG	1980

SUBSTITUTE SHEET (RULE 26)

CAAGGGCTTC ACCACCGCCC GGCTCTGGCA GGTGATGTTT GGCAACCGGA TGCACGGCGC 2040
 CGAACTCGCC CGCGACGACC TGGTCGCGCT CTGCCGCCGC CAGCCGACCG CGACCGCCTC 2100
 GAACGGCGCG ATCGTCGACC TCACCGCGGC CTGCACGGCG CTGTCCCGCT TCGATGAGCG 2160
 TGCCGACCTG GACAGCCGGG GCGCGCACCT GTTCACCGAG TTCGCCCTCG CGGGCGGAAT 2220
 CAGGTTCGCC GACACCTTCG AGGTGACCGA TCCGGTACGC ACCCCGCGCC GTCTGAACAC 2280
 CACGGATCCG CCGGTACGGA CCGCGCTCGC CGACCGCGTG CAACGGCTCG CGGGCATCCC 2340
 CCTCGACGCG AAGCTGGGAG ACATCCACAC CGACAGCCGC GCGGAACGGC GCATCCCCAT 2400
 CCACGGTGGC CGCGGGGAAG CAGGCACCTT CAACGTGATC ACCAACCOCG TCGTGCCGGG 2460
 CGTGGGATAC CCGCAGGTCG TCCACGGAAC ATCGTTCTGT ATGGCCGTCG AACTCGGCC 2520
 GCACGGCCCG TCGGGACGGC AGATCCTCAC CTATGCGCAG TCGACGAACC CGAACTCACC 2580
 CTGGTACGCC GACCAGACCG TGCTCTACTC GCGGAAGGGC TGGGACACCA TCAAGTACAC 2640
 CGAGGCGCAG ATCGCGGCCG ACCCGAACCT GCGCGTCTAC CCGGTGGCAC AGCGGGGACG 2700
 CTGACCCACG TCACGCCGGC TCGGCCCGTG CGGGGGGCGA GGGCGCCGAT CGTCTCTGCA 2760
 TCGCCGGTCA GCCGGGGCCT GCGTCGACCG GCGGCGGCCG GTCGACGCCG GCGTCCCGGC 2820
 GCAGCGACTG GCTGAAGCGC CAGGCGTCGG CGGCCCGGGG CAGGTGTGTG AACATCACGT 2880
 ACGCCGGGCC GCGGTCGAGG ATGCCGGCGA GGTGTGCCAG CTCGGCATCC GTATACACAT 2940
 GCGGGGCGCC GGTGATGCCG TGCAGCCGGT AATAGGCCAT CGGCGTCAGA CTGCGGCGCA 3000
 GGAACGGGTC GCGGCGGTGG GTCAGGTCCA GTCCTTGGCA CAAGCCCTCG ACCACCTCGT 3060
 CCGGCCACGG GCCGCGCGGC TCCACAACA GCGGACACC GGC CGGCCGG CGCGCTCGGG 3120
 CGCAGAACTC ACGCAGTCGC GCGATGGCGG GTTCGGTCGG CCGGAAACTC GCCGGGCACT 3180
 GCAGGTCGAC TCTAGAGGAT CCCCGGTAC CGAGCTCGAA TT 3222

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3193 nucleotides
 (B) TYPE: nucleotide
 (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: polynucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

GATGGTGCTG CACGACCTGA GCCTGGCCGC CCGGTACGCC GACCGGCTGA TCGCGATGAA 60
 GGACGGCCCG ATCGTGGCGA GCGGGGCGCC GGACGAGGTG CTCACCCCGG CGCTGCTGTA 120

SUBSTITUTE SHEET (RULE 26)

- 65 -

GTCGGTCTTC GGGCTGCGCG CGATGGTGGT GCCCGACCCG GCGACCGGCA CCCCCTGGT	180
GATCCCCCTG CCGCGCACCG CCACCTCGGT GCGGGCCTGA AATCGATGAG CGTGGTTGCT	240
TCATCGGCCT GCCGAGCGAT GAGAGTATGT GGGCGGTAGA GCGAGTCTCG AGGGGGAGAT	300
GCCGCGGTGA CGTCTCGTA CATGCGCCTG AAAGCAGCAG CGATCGCCTT CGGTGTGATC	360
GTGGCGACCG CAGCCGTGCC GTCACCGCT TCCGGCAGGG AACATGACGG CGGCTATGCG	420
GCCCTGATCC GCCGGGCCTC GTACGGCGTC CCGCACATCA CCGCCGACGA CTTCGGGAGC	480
CTCGGTTTCG GCGTCGGTA CGTGCAGGCC GAGGACAACA TCTGCGTCAT CGCCGAGAGC	540
GTGGTAACGG CCAACGGTGA GCGGTGCGGG TGGTTGGTG CGACCGGGCC GGACGACGCC	600
GATGTGCGCA GCGACCTCTT CCACCGCAAG GCGATCGACG ACCGCGTCGC CGAGCGGCTC	660
CTCGAAGGGC CCGCGACGG CGTGGGGCG CCGTCGGACG ACGTCCGGGA CCAGATGCGC	720
GGCTTCGTG CCGGCTACAA CCACTTCCTA CGCCGCACCG GCGTGACCG CCTGACCGAC	780
CCGGCGTGCC GCGGCAAGGC CTGGGTGCG CCGCTCTCCG AGATCGATCT CTGGCGTACG	840
TCGTGGGACA GCATGGTCCG GCGCGGTTC GGGGCGCTGC TCGACGGCAT CGTCGCCGCG	900
ACGCCACCTA CAGCCGCCGG GCCCGGTCA GCCCGGAGG CACCCGACGC CGCCGCGATC	960
GCCGCCGCCC TCGACGGGAC GAGCGCGGGC ATCGGCAGCA ACGCGTACGG CCTCGGCGCG	1020
CAGGCCACCG TGAACGGCAG CGGGATGGTG CTGGCCAACC CGCACTTCCC GTGGCAGGGC	1080
GCCGAACGCT TCTACCGGAT GCACCTCAAG GTGCCCGGCC GCTACGACGT CGAGGGCGCG	1140
GCGCTGATCG GCGACCCGAT CATCGGGATC GGGCACAACC GCACGGTCGC CTGGAGCCAC	1200
ACCGTCTCCA CCGCCGCGCG GTTCGTGTGG CACCGCCTGA GCCTCGTGCC CGGCGACCCC	1260
ACCTCTATT ACGTCGACGG CCGGCCGAG CGGATGCGCG CCCGCACGGT CACGGTCCAG	1320
ACCGGCAGCG GCCCGGTGAG CCGCACCTTC CACGACACC GCTACGGCCC GGTGGCCGTG	1380
ATGCCGGGCA CCTTCGACTG GACGCCGGCC ACCCGGTACG CCATCACCGA CGTCAACGCG	1440
GGCAACAACC GCGCCTTGA CGGGTGGCTG CGGATGGGCC AGGCCAAGGA CGTCCGGGCG	1500
CTCAAGGCGG TCCTCGACCG GCACCACTTC CTGCCCTGGG TCAACGTGAT CGCCGCGAC	1560
GCGCGGGGCG AGGCCCTCTA CCGCGATCAT TCGGTCTGCC CCGGGGTGAC CGGCGCGCTC	1620
GCTGCCGCT GCATCCCGGC GCGTTCCAG CCGCTCTACG CCTCCAGCGG CCAGGCGGTC	1680
CTGGACGGTT CCGGTCGGA CTGCGCGCTC GCGCCGACC CCGACGCGCG GGTCCCGGGC	1740
ATTCTCGGCC CCGCGAGCCT GCGGTGCGG TTCGCGACG ACTACGTCAC CAACTCCAAC	1800
GACAGTCACT GGCTGGCCAG CCGGCCGCC CCGCTGGAAG GCTTCCGCG GATCCTCGGC	1860

SUBSTITUTE SHEET (RULE 26)

```

AACGAACGCA CCCCGCGCAG CCTGCGCACC CGGCTCGGGC TGGACCAGAT CCAGCAGCGC 1920
CTCGCCGGCA CGGACGGTCT GCCCGGCAAG GGCCTCACCA CCGCCCGGCT CTGGCAGGTC 1980
ATGTTCCGCA ACCGGATGCA CGGCGCCGAA CTCGCCCCGG ACGACCTGGT CGCGCTCTGC 2040
CGCCGCCAGC CGACCGCGAC CGCCTCGAAC GCGCGCATCG TCGACCTCAC CGCGGCCTGC 2100
ACGGCGCTGT CCCGCTTCGA TGAGCGTGCC GACCTGGACA GCCGGGGCGC GCACCTGTTC 2160
ACCGAGTTCG CCCTCGCGGG CGGAATCAGG TTCGCGACA CCTTCGAGGT GACCGATCCG 2220
GTACGCACCC CGCGCCGTCT GAACACCACG GATCCGCGGG TACGGACGCG GCTCGCCGAC 2280
GCCGTGCAAC GGCTCGCCGG CATCCCCCTC GACGCGAAGC TGGGAGACAT CCACACCGAC 2340
AGCCCGCGCG AACGGCGCAT CCCCATCCAC GGTGGCCGCG GGGAAGCAGG CACCTTCAAC 2400
GTGATCACCA ACCCGCTCGT GCCGGGCGTG GGATACCCGC AGGTCGTCCA CGGAACATCG 2460
TTCGTGATGG CGTTCGAACT CGSCCCGAC GCGCCGTCGG GACGGCAGAT CCTCACCTAT 2520
GCGCAGTCGA CGAACCCGAA CTCACCCTGG TACGCGACC AGACCGTGCT CTA CTGCGCGG 2580
AAGGGCTGGG ACACCATCAA GTACACCGAG GCGCAGATCG CGGCCGACCC GAACCTGCGC 2640
GTCTACCGGG TGGCACAGCG GGGACGCTGA CCCACGTCAC GCGGCTCGG CCCGTGCGGG 2700
GGCGCAGGGC GCGGATCGTC TCTGCATCGC CGGTCAGCCG GGGCCTGCGT CGACCGGCGG 2760
CGGCCGGTCG AGCCCCGCGT CCCGGGCGAG CGACTGGCTG AAGCGCCAGG CGTCGGCGGC 2820
CCGGGGCAGG TTGTTGAACA TCAGTACGC CGGGCCGCCG TCGAGGATGC CGGCGAGGTG 2880
TGCCAGCTCG GCATCCGTAT ACACATGCCG GCGCGCGGTG ATGCCGTGCA GCCGGTAATA 2940
GGCCATCGGC GTCAGACTGC GCGCAGGAA CGGGTCGGCG GCGTGGGTCA GGTCAGCTC 3000
CTGGCACAAG CCCTCGACCA CTCGTCCGG CCACGGGCCG CGCGGCTCCC ACAACAGCCG 3060
GACACCGGCC GGCCGGCGCG CTCGGGCGCA GAACTCACGC AGTCGCGCGA TGGCGGGTTC 3120
GGTCGGCCCG AACTCGCCG GGCACGTCAG GTCGACTCTA GAGGATCCCC GGTACCGAG 3180
CTCGAATTCG TTA 3193

```

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3193 nucleotides
- (B) TYPE: nucleotide
- (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: polynucleotide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

SUBSTITUTE SHEET (RULE 26)

- 67 -

ATCGATGAGC GTGGTTGCTT CATCGGCCTG CCGAGCGATG AGAGTATGTG GCGGTTAGAG	60
CGAGTCTCGA GGGGAGATG CCGCCGTGAC GTCCTCGTAC ATGCGCCTGA AAGCAGCAGC	120
GATCGCCTTC GGTGTGATCG TGGCGACCGC AGCCGTGCCG TCACCCGCTT CCGGCAGGGA	180
ACATGACGGC GGCTATGCGG CCCTGATCCG CCGGGCCTCG TACGGCGTCC CGCACATCAC	240
CGCCGACGAC TTCGGGAGCC TCGGTTTCGG CGTCGGGTAC GTGCAGGCCG AGGACAACAT	300
CTGCGTCATC GCCGAGAGCG TGGTGACGGC CAACGGTGAG CGGTCGCGGT GGTTCGGTGC	360
GACCGGGCCG GACGACGCGG ATGTGCGCAG CGACCTCTTC CACCGCAAGG CGATCGACGA	420
CCGCGTCGCC GAGCGGCTCC TCGAAGGGCC CCGCGACGGC GTGCGGGCGC CGTCGGACGA	480
CGTCCGGGAC CAGATGCGCG GCTTCGTGCG CCGCTACAAC CACTTCCTAC GCCGCACCGG	540
CGTGACCCGC CTGACCGACC CGGCGTGCCG CGGCAAGGCC TGGGTGCGCC CGCTCTCCGA	600
GATCGATCTC TGGCGTACGT CGTGGGACAG CATGGTCCGG GCCGTTCCG GGGCGCTGCT	660
CGACGGCATC GTCGCGCGCA CGCCACCGAC AGCCGCCGGG CCCGCGTCAG CCCCGAGGC	720
ACCCGACGCC GCCGCGATCG CCGCCGCCCT CGACGGGACG AGCGCGGGCA TCGGCAGCAA	780
CGCGTACGGC CTCGGCGCGC AGGCCACCGT GAACGGCAGC GGGATGGTGC TGGCCAACCC	840
GCACTTCCCG TGGCAGGGCG CCGAACGCTT CTACCGGATG CACCTCAAGG TGCCCGGCCG	900
CTACGACGTC GAGGGCGCGG CGTGATCGG CGACCGATC ATCGAGATCG GGCACAACCG	960
CACGGTCGCC TGGAGCCACA CCGTCTCCAC CGCCCGCCGG TTCGTGTGGC ACCGCCTGAG	1020
CCTCGTGCCC GGCAGCCCCA CCTCTATTA CGTCGACGGC CGGCCCGAGC GGATGCGCGC	1080
CCGCACGGTC ACGGTCCAGA CCGGCAGCGG CCCGGTCAGC CGCACCTTCC ACGACACCCG	1140
CTACGGCCCG GTGGCCGTGG TGCCGGGCAC CTTGCACTGG ACGCCGGCCA CCGCGTACGC	1200
CATCACCGAC GTCAACGCGG GCAACAACCG CGCCTTCGAC GGGTGGCTGC GGATGGGCCA	1260
GGCCAAGGAC GTCCGGGCGC TCAAGGCGGT CCTCGACCGG CACCAGTTCC TGCCCTGGGT	1320
CAACGTGATC GCCGCCGACG CGCGGGGCGA GGCCCTCTAC GGCATCAIT CGGTGCTCCC	1380
CCGGGTGACC GGCAGCTCG CTGCCGCTG CATCCCGCGG CGGTTCAGC CGCTCTACGC	1440
CTCCAGCGGC CAGGCGGTCC TGGACGTTT CCGGTGCGAC TGGCGCTCG GCGCCGACCC	1500
CGACGCCCGG GTCCCGGCA TTCTCGGCC GGCAGCCTG CCGGTGCGGT TCCGCGACGA	1560
CTACGTCAAC AACTCCAACG ACAGTCACTG GCTGGCCAGC CCGGCCGCC CGCTGGAAGG	1620
CTTCCCGCG ATCTCGGCA ACGAACGAC CCCGCGCAGC CTGCGCACCC GGCTCGGGCT	1680
GGACCAGATC CAGCAGCGCC TCGCCGGCAC GGACGGTCTG CCCGGCAAGG GCTTCACCAC	1740

SUBSTITUTE SHEET (RULE 26)

- 68 -

CGCCCGGCTC TGGCAGGTCA TGTTCGGCAA CCGGATGCAC GCGGCCGAAC TCGTCCGCGA 1800
CGACCTGGTC GCGCTCTGCC GCGCCAGCC GACCGCGACC GCCTCGAAGC GCGCGATCGT 1850
CGACCTCACC GCGGCCTGCA CGGCGCTGTC CCGCTTCGAT GAGCGTGCCG ACCTGGACAG 1920
CGGGGGCGCG CACCTGTTCA CCGAGTTCGC CCTCGCGGGC GGAATCAGGT TCGCCGACAC 1980
CTTCGAGGTG ACCGATCCGG TACGCACCCC GCGCCGTCTG AACACCACGG ATCCGCGGGT 2040
ACGGACGGCG CTCGCGACG CCGTGCAACG GCTCGCGGCG ATCCCCCTCG ACGCGAAGCT 2100
GGGAGACATC CACACCGACA GCGCGGGCGA ACGGCGCATC CCCATCCAGC GTGGCCGCGG 2160
GGAAGCAGGC ACCTTCAACG TGATCACCAA CCGCTCGTG CCGGGCGTGG GATACCCGCA 2220
GGTCGTCCAC GGAACATCGT TCGTGATGGC CGTCGAACTC GGCCCGCACG GCCCGTCGGG 2280
ACGGCAGATC CTCACCTATG CGCAGTCGAC GAACCCGAAC TCACCCTGGT ACGCCGACCA 2340
GACCGTGCTC TACTCGCGGA AGGGCTGGGA CACCATCAAG TACACCGAGG CGCAGATCGC 2400
GGCCGACCCG AACCTGCGCG TCTACCGGGT GGCACAGCGG GGACGCTGAC CCACGTCACG 2460
CCGGCTCGGC CCGTGCGGGG GCGCAGGGCG CCGATCGTCT CTGCATCGCC GGTGAGCCGG 2520
GGCTGCGTC GACCGCGCGG GCGCGTCTGA CGCCCGGCTC CCGGCGCAGC GACTGGCTGA 2580
AGCGCCAGGC GTCGGCGGCC CGGGGCAGGT TGTGAACAT CACGTACGCC GGGCCGCCGT 2640
CGAGGATGCC GCGGAGGTGT GCCAGCTCGG CATCCGTGTA CACATGCCGG GCGCCGCTGA 2700
TGCGGTGCAG CCGGTAATAG GCCATCGGCG TCAGACTGCG GCGCAGGAAC GGGTCGGCGG 2760
CGTGGGTGAG GTCCAGCTCC TGGCACAAAG CCTCGACCAC CTCGTCCGGC CACGGGCGGC 2820
GCGGCTCCCA CAACAGCCGG ACACCGGCCG GCCGGCGCGC TCGGGCGCAG AACTCACGCA 2880
GTCGCGCGAT GCGGGGTTTC GTGCGCCGGA AACTCGCCGG GCACTGCAG 2929

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 782 amino acids
(B) TYPE: amino acid
(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

Met Arg Leu Lys Ala Ala Ala Ile Ala Phe Gly Val Ile Val Ala Thr
5 10 15
Ala Thr Val Pro Ser Pro Ala Ser Gly Arg Glu His Asp Gly Gly Tyr
20 25 30

SUBSTITUTE SHEET (RULE 26)

- 69 -

Ala Ala Leu Ile Arg Arg Ala Ser Tyr Gly Val Pro His Ile Thr Ala
 35 40 45
 Asp Asp Phe Gly Ser Leu Gly Phe Gly Val Gly Tyr Val Gln Ala Glu
 50 55 60
 Asp Asn Ile Cys Val Ile Ala Glu Ser Val Val Thr Ala Asn Gly Glu
 65 70 75 80
 Arg Ser Arg Trp Phe Gly Ala Thr Gly Pro Asp Asp Ala Asp Val Arg
 85 90 95
 Ser Asp Leu Phe His Arg Lys Ala Ile Asp Asp Arg Val Ala Glu Arg
 100 105 110
 Leu Leu Glu Gly Pro Arg Asp Gly Val Arg Ala Pro Ser Asp Asp Val
 115 120 125
 Arg Asp Gln Met Arg Gly Phe Val Ala Gly Tyr Asn His Phe Leu Arg
 130 135 140
 Arg Thr Gly Val His Arg Leu Thr Asp Pro Ala Cys Arg Gly Lys Ala
 145 150 155 160
 Trp Val Arg Pro Leu Ser Glu Ile Asp Leu Trp Arg Thr Leu Trp Asp
 165 170 175
 Ser Met Val Arg Ala Gly Ser Gly Ala Leu Leu Asp Gly Ile Val Ala
 180 185 190
 Ala Thr Pro Pro Thr Ala Ala Gly Pro Ala Ser Ala Pro Glu Ala Pro
 195 200 205
 Asp Ala Ala Ala Ile Ala Ala Ala Leu Asp Gly Thr Ser Ala Gly Ile
 210 215 220
 Gly Ser Asn Ala Tyr Gly Leu Gly Ala Gln Ala Thr Val Asn Gly Ser
 225 230 235 240
 Gly Met Val Leu Ala Asn Pro His Phe Pro Trp Gln Gly Ala Ala Arg
 245 250 255
 Phe Tyr Arg Met His Leu Lys Val Pro Gly Arg Tyr Asp Val Glu Gly
 260 265 270
 Ala Ala Leu Val Gly Asp Pro Ile Ile Glu Ile Gly His Asn Arg Thr
 275 280 285
 Val Ala Trp Ser His Thr Val Ser Thr Ala Arg Arg Phe Val Trp His
 290 295 300
 Arg Leu Ser Leu Val Pro Gly Asp Pro Thr Ser Tyr Tyr Val Asp Gly
 305 310 315 320
 Arg Pro Glu Arg Met Arg Ala Arg Thr Val Thr Val Gln Thr Gly Ser
 325 330 335
 Gly Pro Val Ser Arg Thr Phe His Asp Thr Arg Tyr Gly Pro Val Ala

SUBSTITUTE SHEET (RULE 26)

- 70 -

	340		345		350
Val Met	Pro Gly Thr Phe Asp Trp Thr Pro Ala Thr Ala Tyr Ala Ile				
	355		360		365
Thr Asp Val Asn Ala Gly Asn Asn Arg Ala Phe Asp Gly Trp Leu Arg					
	370		375		380
Met Gly Gln Ala Lys Asp Val Arg Ala Leu Lys Ala Val Leu Asp Arg					
	385		390		395
His Gln Phe Leu Pro Trp Val Asn Val Ile Ala Ala Asp Ala Arg Gly					
		405		410	415
Glu Ala Leu Tyr Gly Asp His Ser Val Val Pro Arg Val Thr Gly Ala					
	420		425		430
Leu Ala Ala Ala Cys Ile Pro Ala Pro Phe Gln Pro Leu Tyr Ala Ser					
	435		440		445
Ser Gly Gln Ala Val Leu Asp Gly Ser Arg Ser Asp Cys Ala Leu Gly					
	450		455		460
Ala Asp Pro Asp Ala Ala Val Pro Gly Ile Leu Gly Pro Ala Ser Leu					
	465		470		475
Pro Val Arg Phe Arg Asp Asp Tyr Val Thr Asn Ser Asn Asp Ser His					
		485		490	495
Trp Leu Ala Ser Pro Ala Ala Pro Leu Glu Gly Phe Pro Arg Ile Leu					
		500		505	510
Gly Asn Glu Arg Thr Pro Arg Ser Leu Arg Thr Arg Leu Gly Leu Asp					
	515		520		525
Gln Ile Gln Gln Arg Leu Ala Gly Thr Asp Gly Leu Pro Gly Lys Gly					
	530		535		540
Phe Thr Thr Ala Arg Leu Trp Gln Val Met Phe Gly Asn Arg Met His					
	545		550		555
Gly Ala Glu Leu Ala Arg Asp Asp Leu Val Ala Leu Cys Arg Arg Gln					
		565		570	575
Pro Thr Ala Thr Ala Ser Asn Gly Ala Ile Val Asp Leu Thr Ala Ala					
		580		585	590
Cys Thr Ala Leu Ser Arg Phe Asp Glu Arg Ala Asp Leu Asp Ser Arg					
	595		600		605
Gly Ala His Leu Phe Thr Glu Phe Ala Leu Ala Gly Gly Ile Arg Phe					
	610		615		620
Ala Asp Thr Phe Glu Val Thr Asp Pro Val Arg Thr Pro Arg Arg Leu					
	625		630		635
Asn Thr Thr Asp Pro Arg Val Arg Thr Ala Leu Ala Asp Ala Val Gln					
		645		650	655

SUBSTITUTE SHEET (RULE 26)

Arg Leu Ala Gly Ile Pro Leu Asp Ala Lys Leu Gly Asp Ile His Thr
 660 665 670
 Asp Ser Arg Gly Glu Arg Arg Ile Pro Ile His Gly Gly Arg Gly Glu
 675 680 685
 Ala Gly Thr Phe Asn Val Ile Thr Asn Pro Leu Val Pro Gly Val Gly
 690 695 700
 Tyr Pro Gln Val Val His Gly Thr Ser Phe Val Met Ala Val Glu Leu
 705 715 715 720
 Gly Pro His Gly Pro Ser Gly Arg Gln Ile Leu Thr Tyr Ala Gln Ser
 725 730 735
 Thr Asn Pro Asn Ser Pro Trp Tyr Ala Asp Gln Thr Val Leu Tyr Ser
 740 745 750
 Arg Lys Gly Trp Asp Thr Ile Lys Tyr Thr Glu Ala Gln Ile Ala Ala
 755 760 765
 Asp Pro Asn Leu Arg Val Tyr Arg Val Ala Gln Arg Gly Arg
 770 775 780 782

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 782 amino acids
 (B) TYPE: amino acid
 (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

Met Arg Leu Lys Ala Ala Ala Ile Ala Phe Gly Val Ile Val Ala Thr
 5 10 15
 Ala Ala Val Pro Ser Pro Ala Ser Gly Arg Glu His Asp Gly Gly Tyr
 20 25 30
 Ala Ala Leu Ile Arg Arg Ala Ser Tyr Gly Val Pro His Ile Thr Ala
 35 40 45
 Asp Asp Phe Gly Ser Leu Gly Phe Gly Val Gly Tyr Val Gln Ala Glu
 50 55 60
 Asp Asn Ile Cys Val Ile Ala Glu Ser Val Val Thr Ala Asn Gly Glu
 65 70 75 80
 Arg Ser Arg Trp Phe Gly Ala Thr Gly Pro Asp Asp Ala Asp Val Arg
 85 90 95
 Ser Asp Leu Phe His Arg Lys Ala Ile Asp Asp Arg Val Ala Glu Arg
 100 105 110

SUBSTITUTE SHEET (RULE 26)

Leu Leu Glu Gly Pro Arg Asp Gly Val Arg Ala Pro Ser Asp Asp Val
 115 120 125
 Arg Asp Gln Met Arg Gly Phe Val Ala Gly Tyr Asn His Phe Leu Arg
 130 135 140
 Arg Thr Gly Val His Arg Leu Thr Asp Pro Ala Cys Arg Gly Lys Ala
 145 150 155 160
 Trp Val Arg Pro Leu Ser Glu Ile Asp Leu Trp Arg Thr Ser Trp Asp
 165 170 175
 Ser Met Val Arg Ala Gly Ser Gly Ala Leu Leu Asp Gly Ile Val Ala
 180 185 190
 Ala Thr Pro Pro Thr Ala Ala Gly Pro Ala Ser Ala Pro Glu Ala Pro
 195 200 205
 Asp Ala Ala Ala Ile Ala Ala Ala Leu Asp Gly Thr Ser Ala Gly Ile
 210 215 220
 Gly Ser Asn Ala Tyr Gly Leu Gly Ala Gln Ala Thr Val Asn Gly Ser
 225 230 235 240
 Gly Met Val Leu Ala Asn Pro His Phe Pro Trp Gln Gly Ala Glu Arg
 245 250 255
 Phe Tyr Arg Met His Leu Lys Val Pro Gly Arg Tyr Asp Val Glu Gly
 260 265 270
 Ala Ala Leu Ile Gly Asp Pro Ile Ile Gly Ile Gly His Asn Arg Thr
 275 280 285
 Val Ala Trp Ser His Thr Val Ser Thr Ala Arg Arg Phe Val Trp His
 290 295 300
 Arg Leu Ser Leu Val Pro Gly Asp Pro Thr Ser Tyr Tyr Val Asp Gly
 305 310 315 320
 Arg Pro Glu Arg Met Arg Ala Arg Thr Val Thr Val Gln Thr Gly Ser
 325 330 335
 Gly Pro Val Ser Arg Thr Phe His Asp Thr Arg Tyr Gly Pro Val Ala
 340 345 350
 Val Met Pro Gly Thr Phe Asp Trp Thr Pro Ala Thr Ala Tyr Ala Ile
 355 360 365
 Thr Asp Val Asn Ala Gly Asn Asn Arg Ala Phe Asp Gly Trp Leu Arg
 370 375 380
 Met Gly Gln Ala Lys Asp Val Arg Ala Leu Lys Ala Val Leu Asp Arg
 385 390 395 400
 His Gln Phe Leu Pro Trp Val Asn Val Ile Ala Ala Asp Ala Arg Gly
 405 410 415
 Glu Ala Leu Tyr Gly Asp His Ser Val Val Pro Arg Val Thr Gly Ala

SUBSTITUTE SHEET (RULE 26)

420	425	430
Leu Ala Ala Ala Cys Ile Pro Ala Pro Phe Gln Pro Leu Tyr Ala Ser 435	440	445
Ser Gly Gln Ala Val Leu Asp Gly Ser Arg Ser Asp Cys Ala Leu Gly 450	455	460
Ala Asp Pro Asp Ala Ala Val Pro Gly Ile Leu Gly Pro Ala Ser Leu 465	470	475 480
Pro Val Arg Phe Arg Asp Asp Tyr Val Thr Asn Ser Asn Asp Ser His 485	490	495
Trp Leu Ala Ser Pro Ala Ala Pro Leu Glu Gly Phe Pro Arg Ile Leu 500	505	510
Gly Asn Glu Arg Thr Pro Arg Ser Leu Arg Thr Arg Leu Gly Leu Asp 515	520	525
Gln Ile Gln Gln Arg Leu Ala Gly Thr Asp Gly Leu Pro Gly Lys Gly 530	535	540
Phe Thr Thr Ala Arg Leu Trp Gln Val Met Phe Gly Asn Arg Met His 545	550	555 560
Gly Ala Glu Leu Ala Arg Asp Asp Leu Val Ala Leu Cys Arg Arg Gln 565	570	575
Pro Thr Ala Thr Ala Ser Asn Gly Ala Ile Val Asp Leu Thr Ala Ala 580	585	590
Cys Thr Ala Leu Ser Arg Phe Asp Glu Arg Ala Asp Leu Asp Ser Arg 595	600	605
Gly Ala His Leu Phe Thr Glu Phe Ala Leu Ala Gly Gly Ile Arg Phe 610	615	620
Ala Asp Thr Phe Glu Val Thr Asp Pro Val Arg Thr Pro Arg Arg Leu 625	630	635 640
Asn Thr Thr Asp Pro Arg Val Arg Thr Ala Leu Ala Asp Ala Val Gln 645	650	655
Arg Leu Ala Gly Ile Pro Leu Asp Ala Lys Leu Gly Asp Ile His Thr 660	665	670
Asp Ser Arg Gly Glu Arg Arg Ile Pro Ile His Gly Gly Arg Gly Glu 675	680	685
Ala Gly Thr Phe Asn Val Ile Thr Asn Pro Leu Val Pro Gly Val Gly 690	695	700
Tyr Pro Gln Val Val His Gly Thr Ser Phe Val Met Ala Val Glu Leu 705	715	720
Gly Pro His Gly Pro Ser Gly Arg Gln Ile Leu Thr Tyr Ala Gln Ser 725	730	735

SUBSTITUTE SHEET (RULE 26)

Thr Asn Pro Asn Ser Pro Trp Tyr Ala Asp Gln Thr Val Leu Tyr Ser
 740 745 750

Arg Lys Gly Trp Asp Thr Ile Lys Tyr Thr Glu Ala Gln Ile Ala Ala
 755 760 765

Asp Pro Asn Leu Arg Val Tyr Arg Val Ala Gln Arg Gly Arg
 770 775 780 782

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 782 amino acids
 (B) TYPE: amino acid
 (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

Met Arg Leu Lys Ala Ala Ala Ile Ala Phe Gly Val Ile Val Ala Thr
 5 10 15

Ala Thr Val Pro Ser Pro Ala Ser Gly Arg Glu His Asp Gly Gly Tyr
 20 25 30

Ala Ala Leu Ile Arg Arg Ala Ser Tyr Gly Val Pro His Ile Thr Ala
 35 40 45

Asp Asp Phe Gly Ser Leu Gly Phe Gly Val Gly Tyr Val Gln Ala Glu
 50 55 60

Asp Asn Ile Cys Val Ile Ala Glu Ser Val Val Thr Ala Asn Gly Glu
 65 70 75 80

Arg Ser Arg Trp Phe Gly Ala Thr Gly Pro Asp Asp Ala Asp Val Arg
 85 90 95

Ser Asp Leu Phe His Arg Lys Ala Ile Asp Asp Arg Val Ala Glu Arg
 100 105 110

Leu Leu Glu Gly Pro Arg Asp Gly Val Arg Ala Pro Ser Asp Asp Val
 115 120 125

Arg Asp Gln Met Arg Gly Phe Val Ala Gly Tyr Asn His Phe Leu Arg
 130 135 140

Arg Thr Gly Val His Arg Leu Thr Asp Pro Ala Cys Arg Gly Lys Ala
 145 150 155 160

Trp Val Arg Pro Leu Ser Glu Ile Asp Leu Trp Arg Thr Leu Trp Asp
 165 170 175

Ser Met Val Arg Ala Gly Ser Gly Ala Leu Leu Asp Gly Ile Val Ala
 180 185 190

SUBSTITUTE SHEET (RULE 26)

Ala Thr Pro Pro Thr Ala Ala Gly Pro Ala Ser Ala Pro Glu Ala Pro
 195 200 205
 Asp Ala Ala Ala Ile Ala Ala Ala Leu Asp Gly Thr Ser Ala Gly Ile
 210 215 220
 Gly Ser Asn Ala Tyr Gly Leu Gly Ala Gln Ala Thr Val Asn Gly Ser
 225 230 235 240
 Gly Met Val Leu Ala Asn Pro His Phe Pro Trp Gln Gly Ala Ala Arg
 245 250 255
 Phe Tyr Arg Met His Leu Lys Val Pro Gly Arg Tyr Asp Val Glu Gly
 260 265 270
 Ala Ala Leu Val Gly Asp Pro Ile Ile Glu Ile Gly His Asn Arg Thr
 275 280 285
 Val Ala Trp Ser His Thr Val Ser Thr Ala Arg Arg Phe Val Trp His
 290 295 300
 Arg Leu Ser Leu Val Pro Gly Asp Pro Thr Ser Tyr Tyr Val Asp Gly
 305 310 315 320
 Arg Pro Glu Arg Met Arg Ala Arg Thr Val Thr Val Gln Thr Gly Ser
 325 330 335
 Gly Pro Val Ser Arg Thr Phe His Asp Thr Arg Tyr Gly Pro Val Ala
 340 345 350
 Val Val Pro Gly Thr Phe Asp Trp Thr Pro Ala Thr Ala Tyr Ala Ile
 355 360 365
 Thr Asp Val Asn Ala Gly Asn Asn Arg Ala Phe Asp Gly Trp Leu Arg
 370 375 380
 Met Gly Gln Ala Lys Asp Val Arg Ala Leu Lys Ala Val Leu Asp Arg
 385 390 395 400
 His Gln Phe Leu Pro Trp Val Asn Val Ile Ala Ala Asp Ala Arg Gly
 405 410 415
 Glu Ala Leu Tyr Gly Asp His Ser Val Val Pro Arg Val Thr Gly Ala
 420 425 430
 Leu Ala Ala Ala Cys Ile Pro Ala Pro Phe Gln Pro Leu Tyr Ala Ser
 435 440 445
 Ser Gly Gln Ala Val Leu Asp Gly Ser Arg Ser Asp Cys Ala Leu Gly
 450 455 460
 Ala Asp Pro Asp Ala Ala Val Pro Gly Ile Leu Gly Pro Ala Ser Leu
 465 470 475 480
 Pro Val Arg Phe Arg Asp Asp Tyr Val Thr Asn Ser Asn Asp Ser His
 485 490 495
 Trp Leu Ala Ser Pro Ala Ala Pro Leu Glu Gly Phe Pro Arg Ile Leu

SUBSTITUTE SHEET (RULE 26)

500										505										510										
Gly	Asn	Glu	Arg	Thr	Pro	Arg	Ser	Leu	Arg	Thr	Arg	Leu	Gly	Leu	Asp															
	515						520					525																		
Gln	Ile	Gln	Gln	Arg	Leu	Ala	Gly	Thr	Asp	Gly	Leu	Pro	Gly	Lys	Gly															
	530						535					540																		
Phe	Thr	Thr	Ala	Arg	Leu	Trp	Gln	Val	Met	Phe	Gly	Asn	Arg	Met	His															
	545					550				555					560															
Gly	Ala	Glu	Leu	Val	Arg	Asp	Asp	Leu	Val	Ala	Leu	Cys	Arg	Arg	Gln															
				565					570						575															
Pro	Thr	Ala	Thr	Ala	Ser	Asn	Gly	Ala	Ile	Val	Asp	Leu	Thr	Ala	Ala															
				580					585						590															
Cys	Thr	Ala	Leu	Ser	Arg	Phe	Asp	Glu	Arg	Ala	Asp	Leu	Asp	Ser	Arg															
		595					600					605																		
Gly	Ala	His	Leu	Phe	Thr	Glu	Phe	Ala	Leu	Ala	Gly	Gly	Ile	Arg	Phe															
	610						615					620																		
Ala	Asp	Thr	Phe	Glu	Val	Thr	Asp	Pro	Val	Arg	Thr	Pro	Arg	Arg	Leu															
	625					630				635					640															
Asn	Thr	Thr	Asp	Pro	Arg	Val	Arg	Thr	Ala	Leu	Ala	Asp	Ala	Val	Gln															
				645					650						655															
Arg	Leu	Ala	Gly	Ile	Pro	Leu	Asp	Ala	Lys	Leu	Gly	Asp	Ile	His	Thr															
		660					665						670																	
Asp	Ser	Arg	Gly	Glu	Arg	Arg	Ile	Pro	Ile	His	Gly	Gly	Arg	Gly	Glu															
		675					680					685																		
Ala	Gly	Thr	Phe	Asn	Val	Ile	Thr	Asn	Pro	Leu	Val	Pro	Gly	Val	Gly															
	690						695					700																		
Tyr	Pro	Gln	Val	Val	His	Gly	Thr	Ser	Phe	Val	Met	Ala	Val	Glu	Leu															
	705					715				715					720															
Gly	Pro	His	Gly	Pro	Ser	Gly	Arg	Gln	Ile	Leu	Thr	Tyr	Ala	Gln	Ser															
				725					730					735																
Thr	Asn	Pro	Asn	Ser	Pro	Trp	Tyr	Ala	Asp	Gln	Thr	Val	Leu	Tyr	Ser															
				740					745					750																
Arg	Lys	Gly	Trp	Asp	Thr	Ile	Lys	Tyr	Thr	Glu	Ala	Gln	Ile	Ala	Ala															
		755					760						765																	
Asp	Pro	Asn	Leu	Arg	Val	Tyr	Arg	Val	Ala	Gln	Arg	Gly	Arg																	
	770					775						780		782																

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 782 amino acids

SUBSTITUTE SHEET (RULE 26)

(B) TYPE: amino acid
(C) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

```

Met Arg Leu Lys Ala Ala Ala Ile Ala Phe Gly Val Ile Val Ala Thr
      5              10              15
Ala Thr Val Pro Ser Pro Ala Ser Gly Arg Glu His Asp Gly Gly Tyr
      20              25              30
Ala Ala Leu Ile Arg Arg Ala Ser Tyr Gly Val Pro His Ile Thr Ala
      35              40              45
Asp Asp Phe Gly Ser Leu Gly Phe Gly Val Gly Tyr Val Gln Ala Glu
      50              55              60
Asp Asn Ile Cys Val Ile Ala Glu Ser Val Val Thr Ala Asn Gly Glu
      65              70              75              80
Arg Ser Arg Trp Phe Gly Ala Thr Gly Pro Asp Asp Ala Asp Val Arg
      85              90              95
Ser Asp Leu Phe His Arg Lys Ala Ile Asp Asp Arg Val Ala Glu Arg
      100             105             110
Leu Leu Glu Gly Pro Arg Asp Gly Val Arg Ala Pro Ser Asp Asp Val
      115             120             125
Arg Asp Gln Met Arg Gly Phe Val Ala Gly Tyr Asn His Phe Leu Arg
      130             135             140
Arg Thr Gly Val His Arg Leu Thr Asp Pro Ala Cys Arg Gly Lys Ala
      145             150             155             160
Trp Val Arg Pro Leu Ser Glu Ile Asp Leu Trp Arg Thr Leu Trp Asp
      165             170             175
Ser Met Val Arg Ala Gly Ser Gly Ala Leu Leu Asp Gly Ile Val Ala
      180             185             190
Ala Thr Pro Pro Thr Ala Ala Gly Pro Ala Ser Ala Pro Glu Ala Pro
      195             200             205
Asp Ala Ala Ala Ile Ala Ala Ala Leu Asp Gly Thr Ser Ala Gly Ile
      210             215             220
Gly Ser Asn Ala Tyr Gly Leu Gly Ala Gln Ala Thr Val Asn Gly Ser
      225             230             235             240
Gly Met Val Leu Ala Asn Pro His Phe Pro Trp Gln Gly Ala Ala Arg
      245             250             255
Phe Tyr Arg Met His Leu Lys Val Pro Gly Arg Tyr Asp Val Glu Gly
      260             265             270

```

SUBSTITUTE SHEET (RULE 26)

Ala Ala Leu Val Gly Asp Pro Ile Ile Glu Ile Gly His Asn Arg Thr
 275 280 285
 Val Ala Trp Ser His Thr Val Ser Thr Ala Arg Arg Phe Val Trp His
 290 295 300
 Arg Leu Ser Leu Val Pro Gly Asp Pro Thr Ser Tyr Tyr Val Asp Gly
 305 310 315 320
 Arg Pro Glu Arg Met Arg Ala Arg Thr Val Thr Val Gln Thr Gly Ser
 325 330 335
 Gly Pro Val Ser Arg Thr Phe His Asp Thr Arg Tyr Gly Pro Val Ala
 340 345 350
 Val Val Pro Gly Thr Phe Asp Trp Thr Pro Ala Thr Ala Tyr Ala Ile
 355 360 365
 Thr Asp Val Asn Ala Gly Asn Asn Arg Ala Phe Asp Gly Trp Leu Arg
 370 375 380
 Met Gly Gln Ala Lys Asp Val Arg Ala Leu Lys Ala Val Leu Asp Arg
 385 390 395 400
 His Gln Phe Leu Pro Trp Val Asn Val Ile Ala Ala Asp Ala Arg Gly
 405 410 415
 Glu Ala Leu Tyr Gly Asp His Ser Val Val Pro Arg Val Thr Gly Ala
 420 425 430
 Leu Ala Ala Ala Cys Ile Pro Ala Pro Phe Gln Pro Leu Tyr Ala Ser
 435 440 445
 Ser Gly Gln Ala Val Leu Asp Gly Ser Arg Ser Asp Cys Ala Leu Gly
 450 455 460
 Ala Asp Pro Asp Ala Ala Val Pro Gly Ile Leu Gly Pro Ala Ser Leu
 465 470 475 480
 Pro Val Arg Phe Arg Asp Asp Tyr Val Thr Asn Ser Asn Asp Ser His
 485 490 495
 Trp Leu Ala Ser Pro Ala Ala Pro Leu Glu Gly Phe Pro Arg Ile Leu
 500 505 510
 Gly Asn Glu Arg Thr Pro Arg Ser Leu Arg Thr Arg Leu Gly Leu Asp
 515 520 525
 Gln Ile Gln Gln Arg Leu Ala Gly Thr Asp Gly Leu Pro Gly Lys Gly
 530 535 540
 Phe Thr Thr Ala Arg Leu Trp Gln Val Met Phe Gly Asn Arg Met His
 545 550 555 560
 Gly Ala Glu Leu Val Arg Asp Asp Leu Val Ala Leu Cys Arg Arg Gln
 565 570 575
 Pro Thr Ala Thr Ala Ser Asn Gly Ala Ile Val Asp Leu Thr Ala Ala

SUBSTITUTE SHEET (RULE 26)

580	585	590
Cys Thr Ala Leu Ser Arg Phe Asp Glu Arg Ala Asp Leu Asp Ser Arg 595 600 605		
Gly Ala His Leu Phe Thr Glu Phe Ala Leu Ala Gly Gly Ile Arg Phe 610 615 620		
Ala Asp Thr Phe Glu Val Thr Asp Pro Val Arg Thr Pro Arg Arg Leu 625 630 635 640		
Asn Thr Thr Asp Pro Arg Val Arg Thr Ala Leu Ala Asp Ala Val Gln 645 650 655		
Arg Leu Ala Gly Ile Pro Leu Asp Ala Lys Leu Gly Asp Ile His Thr 660 665 670		
Asp Ser Arg Gly Glu Arg Arg Ile Pro Ile His Gly Gly Arg Gly Glu 675 680 685		
Ala Gly Thr Phe Asn Val Ile Thr Asn Pro Leu Val Pro Gly Val Gly 690 695 700		
Tyr Pro Gln Val Val His Gly Thr Ser Phe Val Met Ala Val Glu Leu 705 715 715 720		
Gly Pro His Gly Pro Ser Gly Arg Gln Ile Leu Thr Tyr Ala Gln Ser 725 730 735		
Thr Asn Pro Asn Ser Pro Trp Tyr Ala Asp Gln Thr Val Leu Tyr Ser 740 745 750		
Arg Lys Gly Trp Asp Thr Ile Lys Tyr Thr Glu Ala Gln Ile Ala Ala 755 760 765		
Asp Pro Asn Leu Arg Val Tyr Arg Val Ala Gln Arg Gly Arg 770 775 780 782		

(2) INFORMATION FOR SEQ ID NO: 36:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 782 amino acids
 (B) TYPE: amino acid
 (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

Met Arg Leu Lys Ala Ala Ala Ile Ala Phe Gly Val Ile Val Ala Thr 5 10 15
Ala Ala Val Pro Ser Pro Ala Ser Gly Arg Glu His Asp Gly Gly Tyr 20 25 30
Ala Ala Leu Ile Arg Arg Ala Ser Tyr Gly Val Pro His Ile Thr Ala

SUBSTITUTE SHEET (RULE 26)

35	40	45
Asp Asp Phe Gly Ser Leu Gly Phe Gly Val Gly Tyr Val Gln Ala Glu 50 55 60		
Asp Asn Ile Cys Val Ile Ala Glu Ser Val Val Thr Ala Asn Gly Glu 65 70 75 80		
Arg Ser Arg Trp Phe Gly Ala Thr Gly Pro Asp Asp Ala Asp Val Arg 85 90 95		
Ser Asp Leu Phe His Arg Lys Ala Ile Asp Asp Arg Val Ala Glu Arg 100 105 110		
Leu Leu Glu Gly Pro Arg Asp Gly Val Arg Ala Pro Ser Asp Asp Val 115 120 125		
Arg Asp Gln Met Arg Gly Phe Val Ala Gly Tyr Asn His Phe Leu Arg 130 135 140		
Arg Thr Gly Val His Arg Leu Thr Asp Pro Ala Cys Arg Gly Lys Ala 145 150 155 160		
Trp Val Arg Pro Leu Ser Glu Ile Asp Leu Trp Arg Thr Ser Trp Asp 165 170 175		
Ser Met Val Arg Ala Gly Ser Gly Ala Leu Leu Asp Gly Ile Val Ala 180 185 190		
Ala Thr Pro Pro Thr Ala Ala Gly Pro Ala Ser Ala Pro Glu Ala Pro 195 200 205		
Asp Ala Ala Ala Ile Ala Ala Ala Leu Asp Gly Thr Ser Ala Gly Ile 210 215 220		
Gly Ser Asn Ala Tyr Gly Leu Gly Ala Gln Ala Thr Val Asn Gly Ser 225 230 235 240		
Gly Met Val Leu Ala Asn Pro His Phe Pro Trp Gln Gly Ala Glu Arg 245 250 255		
Phe Tyr Arg Met His Leu Lys Val Pro Gly Arg Tyr Asp Val Glu Gly 260 265 270		
Ala Ala Leu Ile Gly Asp Pro Ile Ile Gly Ile Gly His Asn Arg Thr 275 280 285		
Val Ala Trp Ser His Thr Val Ser Thr Ala Arg Arg Phe Val Trp His 290 295 300		
Arg Leu Ser Leu Val Pro Gly Asp Pro Thr Ser Tyr Tyr Val Asp Gly 305 310 315 320		
Arg Pro Glu Arg Met Arg Ala Arg Thr Val Thr Val Gln Thr Gly Ser 325 330 335		
Gly Pro Val Ser Arg Thr Phe His Asp Thr Arg Tyr Gly Pro Val Ala 340 345 350		

SUBSTITUTE SHEET (RULE 26)

Val Met Pro Gly Thr Phe Asp Trp Thr Pro Ala Thr Ala Tyr Ala Ile
 355 360 365
 Thr Asp Val Asn Ala Gly Asn Asn Arg Ala Phe Asp Gly Trp Leu Arg
 370 375 380
 Met Gly Gln Ala Lys Asp Val Arg Ala Leu Lys Ala Val Leu Asp Arg
 385 390 395 400
 His Gln Phe Leu Pro Trp Val Asn Val Ile Ala Ala Asp Ala Arg Gly
 405 410 415
 Glu Ala Leu Tyr Gly Asp His Ser Val Val Pro Arg Val Thr Gly Ala
 420 425 430
 Leu Ala Ala Ala Cys Ile Pro Ala Pro Phe Gln Pro Leu Tyr Ala Ser
 435 440 445
 Ser Gly Gln Ala Val Leu Asp Gly Ser Arg Ser Asp Cys Ala Leu Gly
 450 455 460
 Ala Asp Pro Asp Ala Ala Val Pro Gly Ile Leu Gly Pro Ala Ser Leu
 465 470 475 480
 Pro Val Arg Phe Arg Asp Asp Tyr Val Thr Asn Ser Asn Asp Ser His
 485 490 495
 Trp Leu Ala Ser Pro Ala Ala Pro Leu Glu Gly Phe Pro Arg Ile Leu
 500 505 510
 Gly Asn Glu Arg Thr Pro Arg Ser Leu Arg Thr Arg Leu Gly Leu Asp
 515 520 525
 Gln Ile Gln Gln Arg Leu Ala Gly Thr Asp Gly Leu Pro Gly Lys Gly
 530 535 540
 Phe Thr Thr Ala Arg Leu Trp Gln Val Met Phe Gly Asn Arg Met His
 545 550 555 560
 Gly Ala Glu Leu Ala Arg Asp Asp Leu Val Ala Leu Cys Arg Arg Gln
 565 570 575
 Pro Thr Ala Thr Ala Ser Asn Gly Ala Ile Val Asp Leu Thr Ala Ala
 580 585 590
 Cys Thr Ala Leu Ser Arg Phe Asp Glu Arg Ala Asp Leu Asp Ser Arg
 595 600 605
 Gly Ala His Leu Phe Thr Glu Phe Ala Leu Ala Gly Gly Ile Arg Phe
 610 615 620
 Ala Asp Thr Phe Glu Val Thr Asp Pro Val Arg Thr Pro Arg Arg Leu
 625 630 635 640
 Asn Thr Thr Asp Pro Arg Val Arg Thr Ala Leu Ala Asp Ala Val Gln
 645 650 655

SUBSTITUTE SHEET (RULE 26)

Arg Leu Ala Gly Ile Pro Leu Asp Ala Lys Leu Gly Asp Ile His Thr
660 665 670

Asp Ser Arg Gly Glu Arg Arg Ile Pro Ile His Gly Gly Arg Gly Glu
675 680 685

Ala Gly Thr Phe Asn Val Ile Thr Asn Pro Leu Val Pro Gly Val Gly
690 695 700

Tyr Pro Gln Val Val His Gly Thr Ser Phe Val Met Ala Val Glu Leu
705 715 715 720

Gly Pro His Gly Pro Ser Gly Arg Gln Ile Leu Thr Tyr Ala Gln Ser
725 730 735

Thr Asn Pro Asn Ser Pro Trp Tyr Ala Asp Gln Thr Val Leu Tyr Ser
740 745 750

Arg Lys Gly Trp Asp Thr Ile Lys Tyr Thr Glu Ala Gln Ile Ala Ala
755 760 765

Asp Pro Asn Leu Arg Val Tyr Arg Val Ala Gln Arg Gly Arg
770 775 780 782

SUBSTITUTE SHEET (RULE 26)

CLAIMSWhat is claimed is:

1. A gene which encodes an enzyme having ECB deacylase activity, said gene comprising a nucleotide sequence which is selected from the group consisting of SEQ. ID. NOS: 26, 27, 28, 29 and 30.

2. An enzyme which exhibits ECB deacylase activity, said enzyme having an amino acid sequence which is selected from the group consisting of SEQ. ID. NOS: 32, 33, 34, 35 and 36.

3. An enzyme which exhibits ECB deacylase activity, said enzyme being made by the method comprising the steps of:

- a) inserting into a vector a double-stranded mutagenized polynucleotide having the SEQ. ID. NOS: 26, 27, 28, 29 or 30 to form an expression vector, said mutagenized polynucleotide encoding an enzyme;
- b) transforming a host cell with said expression vector; and
- c) expressing the enzyme encoded by said mutagenized polynucleotide.

4. A method for producing an enzyme comprising the steps of:

- a) inserting into a vector a double-stranded mutagenized polynucleotide having the SEQ. ID. NOS: 26, 27, 28, 29 or 30 to form an expression vector, said mutagenized polynucleotide encoding an enzyme;
- b) transforming a host cell with said expression vector; and
- c) expressing the enzyme encoded by said mutagenized polynucleotide.

SUBSTITUTE SHEET (RULE 26)

1/14




FIG. 1




FIG. 2




FIG. 3

4/14




FIG. 4





FIG. 5

SUBSTITUTE SHEET (RULE 26)

6/14



forward primers: P50F: 5'-GGCGGAGCTAGCTTCGTA-3' (SEQ. ID. NO: 21)
 (mutagenic primer, underlined base is the mutagenized base at position 598)
 P200F: 5'-GATGTGATGGCTCCTGGC-3' (SEQ. ID. NO: 22)

reverse primers: P80R: 5'-CAGAACACCGATTGAGTT-3' (SEQ. ID. NO: 23)
 P250R: AGTGCTTTCTAAACGATC-3' (SEQ. ID. NO: 24)

FIG. 6

7/14




FIG. 7

SUBSTITUTE SHEET (RULE 26)

8/14




FIG. 8

SUBSTITUTE SHEET (RULE 26)




FIG. 9

SUBSTITUTE SHEET (RULE 26)




FIG.10




FIG.11

12/14







FIG.12

SUBSTITUTE SHEET (RULE 26)

13/14



SUBSTITUTE SHEET (RULE 26)




FIG. 13d





FIG. 13e

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/05814

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : C07H 21/04; C12N 9/18, 15/31, 15/55 US CL : 435/69.1, 320.1; 530/350; 536/23.2 According to International Patent Classification (IPC) or to both national classification and IPC																										
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/69.1, 172.3, 196, 320.1; 530/350; 536/23.2 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.																										
C. DOCUMENTS CONSIDERED TO BE RELEVANT																										
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																								
A	US 5,573,936 A (A. J. KREUZMAN et al.) 12 November 1996.	1-4																								
A	BOECK et al. Deacylation of Echinocandin B by Actinoplanes Utahensis. The Journal of Antibiotics. March 1989, Vol. XLII, No. 3, pages 382-388. See entire document.	1-4																								
A	DEBONO et al. Synthesis of New Analogs of Echinocandin B by Enzymatic Deacylation and Chemical Reacylation of the Echinocandin B Peptide: Synthesis of the Antifungal Agent Cilofungin (LY121019). The Journal of Antibiotics. March 1989, Vol. XLII, No. 3, pages 389-397. See entire document.	1-4																								
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																										
<table border="0"><tr><td colspan="2">* Special categories of cited documents:</td><td>* T</td><td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>* A</td><td>document defining the general state of the art which is not considered to be of particular relevance</td><td>* X</td><td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>* B</td><td>earlier document published on or after the international filing date</td><td>* Y</td><td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>* L</td><td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>* A</td><td>document member of the same patent family</td></tr><tr><td>* O</td><td>document referring to an oral disclosure, use, exhibition or other means</td><td></td><td></td></tr><tr><td>* P</td><td>document published prior to the international filing date but later than the priority date claimed</td><td></td><td></td></tr></table>			* Special categories of cited documents:		* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	* A	document defining the general state of the art which is not considered to be of particular relevance	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	* B	earlier document published on or after the international filing date	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	* L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A	document member of the same patent family	* O	document referring to an oral disclosure, use, exhibition or other means			* P	document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:		* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																							
* A	document defining the general state of the art which is not considered to be of particular relevance	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																							
* B	earlier document published on or after the international filing date	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																							
* L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A	document member of the same patent family																							
* O	document referring to an oral disclosure, use, exhibition or other means																									
* P	document published prior to the international filing date but later than the priority date claimed																									
Date of the actual completion of the international search 14 MAY 1998		Date of mailing of the international search report 30 JUL 1998																								
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer THOMAS G. LARSON, PH.D. Telephone No. (703) 308-0196 																								

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/05814

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN (Agricola, Biosis, Capius, INPADOC, LifeSci, Medline, WPIDS)

Search Terms: ECB, echinocandin, deacylase, Actinoplanes, utahensis.

The computer readable format (CRF) of the sequence listing was found to be defective and could not be processed.

Therefore, a sequence search for SEQ. ID. NOS. 26-30 could not be performed

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)